<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1905222045
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Tysabri
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NATALIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5558.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="VETTER PHARMA-FERTIGUNG, GMBH &amp; CO. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            VETTER PHARMA-FERTIGUNG, GMBH & CO. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Biogen Idec B.V-Natherland
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tysabri is used to treat multiple sclerosis (MS). It contains the active substance natalizumab. This is called a <em>monoclonal antibody</em>.</p><p>&nbsp;</p><p>MS causes inflammation in the brain that damages the nerve cells. This inflammation happens when white blood cells get into the brain and spinal cord. This medicine stops the white blood cells getting through to the brain. This reduces nerve damage caused by MS.</p><p>&nbsp;</p><p><strong>Symptoms</strong> <strong>of multiple sclerosis</strong></p><p>The symptoms of MS vary from patient to patient, and you may experience some or none of them.</p><p>They may include: walking problems; numbness in the face, arms or legs; problems with vision; tiredness; feeling off-balance or light headed; bladder and bowel problems; difficulty in thinking and concentrating; depression; acute or chronic pain; sexual problems; stiffness and muscle spasms.</p><p>&nbsp;</p><p>When the symptoms flare up, it is called a <em>relapse</em> (also known as an exacerbation or an attack). When a relapse occurs, you may notice the symptoms suddenly, within a few hours, or slowly progressing over several days. Your symptoms will then usually improve gradually (this is called a <em>remission</em>).</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>How Tysabri can help</strong></p><p>In trials<strong>,</strong> this medicine approximately halved the build-up of disability caused by MS, and&nbsp; decreased the number of MS attacks by about two-thirds. While you are treated with this medicine you might not notice any improvement, but it may still be working to prevent your MS becoming worse.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before you start treatment with this medicine, it is important that you and your doctor have discussed the benefits you could expect to receive from this treatment and the risks that are associated with it.</p><p>&nbsp;</p><p><strong>You must not be given Tysabri</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; If you are <strong>allergic</strong> to natalizumab or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; If you have been <strong>diagnosed with PML</strong> (<em>progressive multifocal leukoencephalopathy</em>). PML is an uncommon infection of the brain.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; If your <strong>immune system</strong> has a serious problem. This may be due to disease (such as HIV), or to a medicine you are taking, or have taken in the past (see below).</p><p><s>&nbsp;</s></p><p>&middot;&nbsp;&nbsp;&nbsp; If you are taking <strong>medicines that</strong> <strong>affect your immune system</strong>, including certain other medicines used to treat MS. These medicines cannot be used with Tysabri.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; If you <strong>have cancer</strong> (unless it is a type of skin cancer called <em>basal cell carcinoma</em>).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>You need to discuss with your doctor </strong>whether Tysabri is the most suitable treatment for you. Do this before you start taking this medicine, and when you have been receiving&nbsp; it for more than two years.</p><p><u>&nbsp;</u></p><p><strong>Possible brain infection (PML)</strong></p><p>&nbsp;</p><p>Some people receiving this medicine (fewer than 1 in 100) have had an uncommon brain infection called PML (<em>progressive multifocal leukoencephalopathy</em>). PML can lead to severe disability or death.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Before starting treatment, <strong>all patients will have</strong> <strong>blood</strong> <strong>tests</strong> arranged by the doctor for JC virus infection. JC virus is a common virus that does not normally make you ill. However, PML is linked to an increase of JC virus in the brain. The reason for this increase in some patients treated with Tysabri is not clear. Before and during treatment, your doctor will test your blood to check if you have antibodies to the JC virus, which are a sign that you have been infected by the JC virus.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Your doctor will arrange a <strong>Magnetic Resonance Imaging (MRI) scan</strong>, which will be repeated during treatment to rule out PML.<br />&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>The symptoms of PML</strong> may be similar to an MS relapse (see section 4, <em>Possible side effects</em>). You can also get PML up to 6 months after stopping Tysabri treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor as soon as possible</strong> if you notice your MS getting worse or if you notice any new symptoms, while you are on Tysabri treatment or for up to 6 months afterwards.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Tell your partner or caregivers</strong> about what to look out for (see also section 4, <em>Possible side effects</em>). Some symptoms might be difficult to spot by yourself, such as changes in mood or behaviour, confusion, speech and communication difficulties. If you get any of these, <strong>you may need further tests</strong>. Keep looking out for symptoms in the 6 months after stopping Tysabri.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Keep the patient alert card you have been given by your doctor. It includes this information. Show it to your partner or caregivers.</p><p>&nbsp;</p><p><strong>Three things can increase your risk of PML </strong>with Tysabri.<strong> </strong>If you have two or more of these risk factors, the risk is increased further:<strong> </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>If you have antibodies to the JC virus </strong>in your blood. These are a sign that the virus is in your body. You will be tested before and during Tysabri treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>If</strong><strong> you are </strong><strong>treated for a long time </strong>with Tysabri, especially if it is more than two years.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>If you have</strong> <strong>taken a medicine called an <em>immunosuppressant</em></strong>, that reduces the activity of your immune system.</p><p><strong>&nbsp;</strong></p><p><strong>Another condition,</strong> called JCV GCN (<em>JC virus granule cell neuronopathy</em>), is also caused by JC virus and has occurred in some patients receiving this medicine. The symptoms of JCV GCN are similar to PML.</p><p>&nbsp;</p><p><strong>For those with a lower risk of PML</strong>, your doctor may repeat the test regularly to check that:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; You still do not have antibodies to the JC virus in your blood.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; If you have been treated for more than 2 years, you still have a lower level of JC virus antibodies in your blood.</p><p><strong>&nbsp;</strong></p><p><strong>If someone gets PML</strong></p><p>PML can be treated, and Tysabri treatment will be stopped. However, some people <strong>get</strong> <strong>a reaction</strong> as Tysabri is removed from the body. This reaction (known as <strong>IRIS</strong>, or <em>immune reconstitution inflammatory syndrome</em>) may lead to your condition getting worse, including worsening of brain function.</p><p>&nbsp;</p><p><strong>Look out for other infections</strong></p><p>Some infections other than PML may also be serious and can be due to viruses, bacteria, and other causes.</p><p>&nbsp;</p><p><strong>Tell a doctor or nurse</strong> <strong>immediately</strong> if you think you have an infection (see also section 4, <em>Possible side effects</em>).</p><p>&nbsp;</p><p><strong>Changes in blood platelets</strong></p><p>Natalizumab may reduce platelets in the blood which are responsible for clotting. This may result in a condition called thrombocytopenia (see section 4) in which your blood may not clot quickly enough to stop bleeding. This can lead to bruising as well as other more serious problems such as excessive bleeding. You should talk to your doctor immediately if you have unexplained bruising, red or purple spots on the skin (called petechiae), bleeding from skin cuts that does not stop or oozes, prolonged bleeding from the gums or nose, blood in urine or stools, or bleeding in the whites of your eyes.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children or adolescents under the age of 18 years.</p><p>&nbsp;</p><p><strong>Other medicines and Tysabri</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>You </strong><strong>must not be</strong> <strong>given this medicine</strong> if you are now being treated with medicines that affect your <strong>immune system</strong>, including certain other medicines to treat your MS.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; You might not be able to use this medicine if you have <strong>previously </strong>had any medicines that affect your immune system.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Do not use this medicine if you are pregnant</strong>, unless you have discussed this with your doctor. Be sure to tell your doctor immediately if you get pregnant, think you may be pregnant, or if you are planning to become pregnant.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Do not breast‑feed whilst using Tysabri</strong>. Your doctor will help you decide whether you should stop breast‑feeding, or stop using the medicine.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. The risk to the baby and benefit to the mother will be taken into consideration by your doctor.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Dizziness is a very common side effect. If you are affected, do not drive or use machines.</p><p>&nbsp;</p><p><strong>Tysabri contains sodium </strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 300&nbsp;mg dose, so it is essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tysabri injections will be given to you, by a doctor experienced in the treatment of MS. Your doctor may switch you directly from another medicine to Tysabri if there are no signs of problems caused by your previous treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Your doctor will order <strong>blood tests</strong> for antibodies to the JC virus and other possible problems.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Your doctor will arrange an <strong>MRI scan</strong>, which will be repeated during treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>To switch from some MS medicines,</strong> your doctor may advise you to wait for a certain time to ensure that most of the previous medicine has left your body.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; For adults the recommended dose is 300&nbsp;mg, given once every 4&nbsp;weeks.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Each dose is given as <strong>two injections</strong> under the skin, in your thigh, stomach or back of your arm. This takes up to 30&nbsp;minutes.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Information for medical or healthcare professionals on how to prepare and inject the medicine is provided at the end of this leaflet.</p><p>&nbsp;</p><p><strong>If you stop using Tysabri</strong></p><p>Regular dosing with this medicine is important, especially in the first few months of treatment. It is important to continue with your medicine for as long as you and your doctor decide that it is helping you. Patients who received one or two doses of Tysabri, and then had a gap in treatment of three months or more, were more likely to have an allergic reaction when restarting treatment.</p><p>&nbsp;</p><p><strong>Checking for allergic reactions</strong></p><p>A few patients have had an allergic reaction to this medicine. Your doctor may check for allergic reactions during the injections and for 1&nbsp;hour afterwards. See also section 4, <em>Possible side effects</em>.</p><p>&nbsp;</p><p><strong>If you miss your dose of Tysabri</strong></p><p>If you miss your usual dose of Tysabri, arrange with your doctor to receive it as soon as you can. You can then continue to receive your dose of Tysabri every 4&nbsp;weeks.</p><p><strong>&nbsp;</strong></p><p><strong>Will Tysabri always work?</strong></p><p>In a few patients receiving Tysabri, the body&rsquo;s natural defences may stop the medicine from working properly over time, as the body develops antibodies to the medicine. Your doctor can decide whether this medicine is not working properly for you from blood tests and will stop the treatment, if necessary.</p><p>&nbsp;</p><p>If you have any further questions on Tysabri, ask your doctor. Always use this medicine exactly as described in this leaflet or as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p>Subcutaneous is abbreviated as SC on the syringe label.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Speak to your doctor or nurse immediately </strong>if you notice any of the following.</p><p><strong>&nbsp;</strong></p><p><strong>Signs of a brain infection</strong></p><p>&middot;&nbsp;&nbsp; Changes in personality and behaviour such as confusion, delirium or loss of consciousness,</p><p>&middot;&nbsp;&nbsp; Seizures (fits)</p><p>&middot;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp; Nausea / vomiting</p><p>&middot;&nbsp;&nbsp; Stiff neck</p><p>&middot;&nbsp;&nbsp; Extreme sensitivity to bright light</p><p>&middot;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp; Rash (anywhere on the body)</p><p>&nbsp;</p><p>These symptoms may be caused by an infection of the brain (<em>encephalitis or PML</em>) or its covering layer (<em>meningitis</em>).</p><p>&nbsp;</p><p><strong>Signs of other serious infections</strong></p><p>&middot;&nbsp;&nbsp; An unexplained fever</p><p>&middot;&nbsp;&nbsp; Severe diarrhoea</p><p>&middot;&nbsp;&nbsp; Shortness of breath</p><p>&middot;&nbsp;&nbsp; Prolonged dizziness</p><p>&middot;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp; Weight loss</p><p>&middot;&nbsp;&nbsp; Listlessness</p><p>&middot;&nbsp;&nbsp; Impaired vision</p><p>&middot;&nbsp;&nbsp; Pain or redness of the eye(s)</p><p>&nbsp;</p><p><strong>Signs of an allergic reaction</strong></p><p>&middot;&nbsp;&nbsp; Itchy rash (<em>hives</em>)</p><p>&middot;&nbsp;&nbsp; Swelling of your face, lips or tongue</p><p>&middot;&nbsp;&nbsp; Difficulty breathing</p><p>&middot;&nbsp;&nbsp; Chest pain or discomfort</p><p>&middot;&nbsp;&nbsp; Increase or decrease in your blood pressure (your doctor or nurse will notice this if they are monitoring your blood pressure)</p><p>&nbsp;</p><p>These are most likely during or shortly after the injection.</p><p>&nbsp;</p><p><strong>Signs of a possible liver problem</strong></p><p>&middot;&nbsp;&nbsp; Yellowing of your skin or the whites of your eyes</p><p>&middot;&nbsp;&nbsp; Unusual darkening of the urine</p><p>&middot;&nbsp;&nbsp; Abnormal liver function test</p><p>&nbsp;</p><p><strong>Speak to a doctor or nurse immediately </strong>if you get any of the side effects listed above, or if you think you have an infection. <strong>Show</strong> <strong>your patient alert card</strong> and this package leaflet to any doctor or nurse who treats you, not only to your neurologist.</p><p><strong>&nbsp;</strong></p><p><strong>Other side effects</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10&nbsp;people)</p><p>&middot;&nbsp;&nbsp; Urinary tract infection</p><p>&middot;&nbsp;&nbsp; Sore throat and runny or blocked up nose</p><p>&middot;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp; Feeling sick (<em>nausea</em>)</p><p>&middot;&nbsp;&nbsp; Joint pain</p><p>&middot;&nbsp;&nbsp; Tiredness</p><p><strong>&nbsp;</strong></p><p><strong>Common </strong>&nbsp;(may affect up to 1 in 10&nbsp;people)</p><p>&middot;&nbsp;&nbsp; Anaemia (decrease in your red blood cells which can make your skin pale and can make you feel breathless or lacking energy)</p><p>&middot;&nbsp;&nbsp; Allergy (<em>hypersensitivity</em>)</p><p>&middot;&nbsp;&nbsp; Shivering</p><p>&middot;&nbsp;&nbsp; Itchy rash (<em>hives</em>)</p><p>&middot;&nbsp;&nbsp; Being sick (<em>vomiting</em>)</p><p>&middot;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp; Difficulty breathing (<em>dyspnoea</em>)</p><p>&middot;&nbsp;&nbsp; Reddening of the face or body (<em>flushing</em>)</p><p>&middot;&nbsp;&nbsp; Herpes infections</p><p>&middot;&nbsp;&nbsp; Discomfort around the place you have been injected.&nbsp; You could experience pain, bruising, redness, itching or swelling</p><p>&nbsp;</p><p><strong>Uncommon </strong>&nbsp;(may affect up to 1 in 100&nbsp;people)</p><p>&middot;&nbsp;&nbsp; Severe allergy (<em>anaphylactic reaction</em>)</p><p>&middot;&nbsp;&nbsp; Progressive multifocal leukoencephalopathy (PML)</p><p>&middot;&nbsp;&nbsp; Inflammatory disorder after discontinuation of the medicinal product</p><p>&middot;&nbsp;&nbsp; Facial swelling</p><p>&middot;&nbsp;&nbsp; An increase in the number of white blood cells (<em>eosinophilia</em>)</p><p>&middot;&nbsp;&nbsp; Reduction in blood platelets</p><p>&middot;&nbsp;&nbsp; Easy bruising (purpura)</p><p><strong>&nbsp;</strong></p><p><strong>Rare </strong>&nbsp;(may affect up to 1 in 1,000&nbsp;people)</p><p>&middot;&nbsp;&nbsp;&nbsp; Herpes infection in the eye</p><p>&middot;&nbsp;&nbsp; Severe anaemia (decrease in your red blood cells which can make your skin pale and can make you feel breathless or lacking energy)</p><p>&middot;&nbsp;&nbsp; Severe swelling under the skin</p><p>&middot;&nbsp;&nbsp; High levels of bilirubin in the blood (<em>hyperbilirubinaemia) </em>which may cause symptoms such as yellowing of your ees or skin, fever and tiredness</p><p>&nbsp;</p><p><strong>Not known (</strong>frequency cannot be estimated from the available data<strong>)</strong></p><p>&middot;&nbsp;&nbsp; Unusual infections of brain and eyes</p><p>&middot;&nbsp;&nbsp; Damage to your liver</p><p><strong>&nbsp;</strong></p><p><strong>Speak</strong> <strong>to your doctor as soon as possible</strong> if you think you have an infection<em>.</em>You will also find this information in the patient alert card you have been given by your doctor.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><strong>If you get any side effects, talk to your</strong><strong> doctor</strong><strong>.</strong> This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in section 6 of this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&nbsp;</p><ul><li><strong>Other GCC States:</strong></li></ul><p><strong>&nbsp;</strong></p><p>- &nbsp;&nbsp;&nbsp;&nbsp;Please contact the relevant</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date stated on the label and carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2˚C&nbsp;‑&nbsp;8˚C).</p><p>Do not freeze.</p><p>The syringes can be kept in their original packaging for up to 24<strong>&nbsp;</strong>hours at room temperature (up to 25&deg;&nbsp;C).&nbsp; The syringes must not be returned to the refrigerator.&nbsp;</p><p>Keep the syringes in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice particles in the liquid and/or the liquid in the syringe is discoloured.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is natalizumab.</p><p>Each 1 mL pre-filled syringe contains 150&nbsp;mg natalizumab.</p><p><u>&nbsp;</u></p><p>The other ingredients are:</p><p>Sodium phosphate, monobasic, monohydrate,</p><p>Sodium phosphate, dibasic, heptahydrate,</p><p>Sodium chloride (see section 2 &lsquo;Tysabri contains sodium&rsquo;),</p><p>Polysorbate 80 (E 433)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Tysabri is a colourless to slightly yellow, slightly opalescent to opalescent liquid.
	Each carton contains two syringes.
	Tysabri is available in packs containing 2 pre-filled syringes.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Biogen Netherlands B.V.</p><p>Prins Mauritslaan 13</p><p>1171 LP Badhoevedorp</p><p>The Netherlands</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p>Vetter Pharma-Fertigung GmbH &amp; Co. KG</p><p>Schuetzenstrasse 87, 99-101</p><p>Ravensburg</p><p>Baden-Wuerttemberg 88212</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُستعمل تيسابري &nbsp;TYSABRIفي علاج مرض تصلب الأنسجة المتعدد.(MS) &nbsp;ويحتوي الدواء على المادة الفعالة )ناتاليزوماب(NATALIZUMAB &nbsp;تسمى هذه المادة الفعالة <em>الجسم المضاد وحيد النسيلة </em><em>)</em><em>مونوكلونال).</em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">يسبب تصلب الأنسجة المتعدد MS)) التهاب في المخ مما يؤدي إلى إتلاف خلايا الأعصاب. ويحدث هذا الالتهاب عندما تصل خلايا الدم البيضاء إلى المخ والحبل الشوكي. ويعمل تيسابري TYSABRI على منع وصول خلايا الدم البيضاء إلى المخ، وهذا يقلل من تلف الأعصاب الناتج عن مرض تصلب الأنسجة المتعدد MS)).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>هي</strong><strong> </strong><strong>أعراض</strong><strong> </strong><strong>مرض</strong><strong> </strong><strong>تصلب</strong><strong> </strong><strong>الأنسجة</strong><strong> </strong><strong>المتعدد </strong>MS)) <strong>؟</strong></p><p dir="RTL">تختلف أعراض مرض تصلب الأنسجة المتعدد من مريض لآخر، فمن الممكن أن تظهر لديك بعض هذه الأعراض ومن الممكن ألا تظهر لديك أي منها على الإطلاق. وقد تشمل تلك الأعراض<strong>: </strong>مشاكل أثناء المشي، الشعور بخدر في الوجه، أو الذراعين أو الأرجل، مشاكل في الرؤية، التعب، الشعور بفقدان التوازن أو الشعور بالدوار، مشاكل في المثانة والأمعاء، صعوبة في التفكير والتركيز، الاكتئاب، ألم حاد أو مزمن، مشاكل جنسية، تيبس وتشنج في العضلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما تزداد حدة الأعراض تسمى هذه الحالة &nbsp;<em>بالانتكاسة</em> )وتُعرف أيضًا باسم تفاقم الحالة أو أزمة حادة). وعند حدوث الانتكاسة ربما تلاحظ الأعراض فجأة خلال ساعات قليلة أو تزداد ببطء خلال عدة أيام. وعندئذ سوف تتحسن الأعراض تدريجيًّا (وهذا ما يسمى بخمود <em>حدة</em><em> </em><em>المرض).</em></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيف يستطيع تيسابري</strong><strong> TYSABRI </strong><strong>أن يساعدك</strong></p><p dir="RTL"><strong>في</strong><strong> </strong><strong>التجارب</strong><strong> </strong><strong>الإكلينيكية،</strong><strong> </strong>استطاع الدواء تيسابري TYSABRI أن يحد من ازدياد أعراض العجز الناتجة عن تصلب الأنسجة المتعدد MS بمقدار النصف كما أدى أيضًا إلى تخفيض عدد نوبات تصلب الأنسجة المتعدد إلى الثلث. وأثناء العلاج باستخدام تيسابري TYSABRI فربما لا تشعر بأيِّ تحسن ولكن ربما يستمر تيسابري TYSABRI في العمل على منع تفاقم الحالة المرضية الناتجة عن مرض تصلب الأنسجة المتعدد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قبل أن تبدأ العلاج باستعمال تيسابريTYSABRI ، من الضروري أن تناقش أنت وطبيبك المزايا التي قد تتوقع الحصول عليها من هذا العلاج والمخاطر المرتبطة باستعمال هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا</strong><strong> ي</strong><strong>جب أن تتلقى </strong><strong>&nbsp;</strong><strong>تيسابري</strong><strong> TYSABRI </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;إذا كانت لديك <strong>حساسية</strong> تجاه المادة ناتاليزوماب NATALIZUMAB أو أيٍّ من المكونات الأخرى في هذا الدواء )مذكورة في القسم ٦&nbsp; .(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;إذا كنت مصابًا <strong>بمرض</strong><strong> </strong><strong>الالتهاب</strong><strong> </strong><strong>المتقدم</strong><strong> </strong><strong>متعدد</strong><strong> </strong><strong>البؤرات</strong><strong> </strong><strong>لمادة</strong><strong> </strong><strong>الدماغ</strong><strong> </strong><strong>البيضاء</strong> PML وهذه عدوى نادرة في المخ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;إذا كنت تعاني من مشكلة خطيرة في <strong>جهازك</strong><strong> </strong><strong>المناعي</strong> نتيجة لإصابتك بمرض (مثل فيروس نقص المناعة (HIV أو نتيجة لدواء تتناوله أو تناولته من قبل (انظر أدناه).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;إذا كنت تتناول <strong>أدوية</strong><strong> </strong><strong>تؤثر على</strong><strong> </strong><strong>جهازك</strong><strong> </strong><strong>المناعي</strong> بما فيها أدوية لمعالجة مرض التصلب المتعدد. هذه الأدوية لا يمكن استخدامها مع تيسابري TYSABRI .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;إذا كنت مصابًا <strong>بمرض</strong><strong> </strong><strong>السرطان</strong> )ما لم يكن نوع من سرطان الجلد المسمى باسم سرطان <em>كارسينومة</em><em> </em><em>الخلايا</em><em> </em><em>الأساسية</em>).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات</strong><strong> </strong><strong>والاحتياطات</strong></p><p dir="RTL"><strong>يجب عليك أن تستشير طبيبك حتى تعرف </strong>ما إذا كان تيسابري TYSABRI هو العلاج الأنسب لك أم لا. افعل ذلك قبل أن تبدأ في تناول هذا الدواء وإذا كنت تتناوله لأكثر من عامين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>عدوى المخ المحتملة (الالتهاب</strong><strong> </strong><strong>المتقدم</strong><strong> </strong><strong>متعدد</strong><strong> </strong><strong>البؤرات</strong><strong> </strong><strong>لمادة</strong><strong> </strong><strong>الدماغ</strong><strong> </strong><strong>البيضاء</strong> <strong>PML</strong><strong>)</strong></p><p dir="RTL">يعاني بعض الأشخاص الذين يُعالَجون باستخدام هذا الدواء (أقل من 1 في 100) من عدوى دماغية غير شائعة تسمى PML (<em>الالتهاب</em><em> </em><em>المتقدم</em><em> </em><em>متعدد</em><em> </em><em>البؤرات</em><em> </em><em>لمادة</em><em> </em><em>الدماغ</em><em> </em><em>البيضاء</em>). يمكن أن يؤدي مرض PML إلى الإصابة بعجز شديد أو الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;قبل البدء بالعلاج، <strong>سيجري جميع المرضى فحوصات الدم</strong> بالترتيب مع الطبيب المعالج لعدوى فيروس JC. إن فيروس JC &nbsp;هو فيروس شائع لا يسبب في المعتاد أي مرض ملحوظ. ومع ذلك يرتبط هذا المرض PML بزيادة فيروس JC في المخ رغم أن السبب لهذه الزيادة لدى بعض المرضى المعالجين بدواء تيسابريTYSABRI &nbsp;غير معروف. وقبل أن تبدأ العلاج أو أثناء العلاج بدواء تيسابريTYSABRI ، سيقوم طبيبك بفحص الدم للتأكد عما إذا كانت لديك أجسام مضادة لفيروس JC، والتي تُعتبر علامة بأنك قد أصبتَ بفيروس.JC &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;سوف يجري لك الطبيب <strong>فحص أشعة بالرنين المغناطيسيّ</strong>، والذي سيتكرر عدة مرات أثناء العلاج للتأكد من عدم إصابتك بالالتهاب المتقدم متعدد البؤرات لمادة الدماغ البيضاء PML.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;قد تكون <strong>أعراض</strong><strong> </strong><strong>مرض</strong><strong> </strong><strong>الالتهاب</strong><strong> </strong><strong>المتقدم</strong><strong> </strong><strong>متعدد</strong><strong> </strong><strong>البؤرات لمادة</strong><strong> </strong><strong>الدماغ</strong><strong> </strong><strong>البيضاء </strong><strong>PML</strong> مشابهة لانتكاسة مرض تصلب الأنسجة المتعدد MS )انظر القسم 4، <em>الأعراض الجانبية المحتملة</em>). ومن الممكن أن تُصاب بمرض الالتهاب المتقدم المتعدد البؤرات لمادة الدماغ البيضاء PML&nbsp; خلال ٦ أشهر بعد التوقف عن تناول دواء تيسابري TYSABRI .</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;إذا لاحظت أن مرض تصلب الأنسجة لديك قد ازداد سوءًا أو إذا لاحظت أي أعراض جديدة بالفترة التي تستخدم بها علاج تيسابري TYSABRI أو لمدة ٦ أشهر من بعد التوقف عن تناول دواء تيسابريTYSABRI ، فمن الضروري جدًّا أن <strong>تتحدث</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>في</strong><strong> </strong><strong>أسرع</strong><strong> </strong><strong>وقت</strong><strong> </strong><strong>ممكن</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;تحدث</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>شريك</strong><strong> </strong><strong>حياتك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>من</strong><strong> </strong><strong>يقدم</strong><strong> </strong><strong>لك</strong><strong> </strong><strong>الرعاية</strong> وأبلغهم عما يجب أن تحتاط إليه خلال فترة العلاج (انظر القسم 4، <em>الأعراض الجانبية المحتملة</em>). وقد تنشأ أعراض ربما لا تكون أنت نفسك على دراية بها. وذلك مثل التغيرات في المزاج أو السلوك والارتباك والصعوبة في التكلم والتواصل. إذا ظهرت عليك أيٌّ من هذه الأعراض، <strong>قد تحتاج إلى إجراء مزيدٍ من الفحوصات</strong>. لذا يجب أن تبقى متيقظًا &nbsp;للأعراض التي ممكن أن تظهر لمدة 6 أشهر بعد التوقف عن علاج تيسابري TYSABRI. &nbsp;</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;سوف تجد أيضًا هذه المعلومات في بطاقة تنبيه المريض التي أخذتها من طبيبك .ومن الضروري أن تحتفظ بهذه البطاقة التحذيرية وأن تجعل شريك حياتك أو من يقدم لك الرعاية يطّلع عليها.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ثلاثة أمور قد تزيد من خطر إصابتك</strong><strong> </strong><strong>بمرض</strong> <strong>الالتهاب</strong><strong> </strong><strong>المتقدم</strong><strong> </strong><strong>متعدد</strong><strong> </strong><strong>البؤرات</strong><strong> </strong><strong>لمادة</strong><strong> </strong><strong>الدماغ</strong><strong> </strong><strong>البيضاء</strong> <strong>PML</strong><strong> </strong>عند تناول دواء تيسابريTYSABRI <strong>. </strong>إذا كان لديك عاملان أو أكثر من عوامل الخطر المشار إليها، &nbsp;فإن الخطر يزداد:<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;إذا</strong><strong> </strong><strong>كانت</strong><strong> </strong><strong>هناك</strong><strong> </strong><strong>أجسام مضادة</strong><strong> </strong><strong>لفيروس </strong><strong>JC</strong><strong> في</strong><strong> </strong><strong>دمك</strong>، حيث تُعتبر هذه علامة على وجود الفيروس في جسمك. وستخضع للفحص قبل وأثناء العلاج بدواء تيسابريTYSABRI <strong>.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;</strong><strong>كلما</strong><strong> </strong><strong>طالت</strong><strong> </strong><strong>مدة</strong><strong> </strong><strong>العلاج</strong>، وخاصة إذا كنت تُعالج بهذا الدواء لأكثر من سنتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;إذا</strong><strong> </strong><strong>كنتَ قد</strong><strong> </strong><strong>تناولتَ</strong><strong> </strong><strong>من</strong><strong> </strong><strong>قبل <em>دواء مثبطًا للمناعة</em></strong>، الذي يُضعف من نشاط الجهاز المناعي بالجسم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>هناك حالة أخرى</strong> تسمى <em>الاعتلال العصبي الخلوي الحبيبي</em> بفيروس JC (JCV GCN )، هي أيضًا سبب من أسباب فيروس JC وقد حدثت لدى بعض المرضى الذين عولجوا باستخدام دواء تيسابري .TYSABRI إن أعراض &nbsp;JCV GCNتشبه أعراض.PML &nbsp;&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بالنسبة للأشخاص المعرضون لمستوى أقل من مخاطر الإصابة بـــ </strong><strong>PML</strong>، &nbsp;طبيبكم قد يعيد الفحوصات كل فترة لكي يتحقق من:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp; </strong>&nbsp;&nbsp;أن دمك ما زال لا يحتوي على أجسام مضادة لفيروس JC<strong>.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;إذا كنتَ قد تلقيتَ العلاج لأكثر من سنتين ولديك كمية أقل من الأجسام المضادة لفيروس JC في دمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال إصابة أي شخص بمرض</strong><strong> </strong><strong>الالتهاب</strong><strong> </strong><strong>المتقدم</strong><strong> </strong><strong>متعدد</strong><strong> </strong><strong>البؤرات</strong><strong> </strong><strong>لمادة</strong><strong> </strong><strong>الدماغ</strong><strong> </strong><strong>البيضاء </strong><strong>PML</strong></p><p dir="RTL">يمكن علاج مرض PML وسوف يتم التوقف عن تناول دواء تيسابريTYSABRI . ومع ذلك قد يحدث لدى بعض المرضى رد فعل عند زوال آثار دواء تيسابري TYSABRI من الجسم. وقد يؤدي رد الفعل هذا، المعروف <em>بمتلازمة</em><em> </em><em>استنشاء</em><em> </em><em>المناعة</em><em> </em><em>الالتهابية</em> IRIS Immune Reconstitution Inflammatory Syndrome (<em>متلازمة</em><em> </em><em>الاسترداد</em><em> </em><em>المناعي الالتهابية</em>) إلى تدهور حالتك، بما في ذلك وظائف المخ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الانتباه لأيِّ عدوى أخرى</strong></p><p dir="RTL">هناك حالات عدوى أخرى، بخلاف الالتهاب المتقدم المتعدد البؤرات لمادة الدماغ البيضاء PML، والتي قد تكون خطرة أيضًا وقد تسببها الفيروسات والبكتيريا وغيرها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ</strong><strong>بلغ الطبيب أو الممرض على الفور</strong> إذا ظننتَ بأنك قد أُصبتَ بعدوى (انظر القسم 4، <em>الأعراض الجانبية المحتملة</em>).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تغيرات في الصفائح الدموية</strong></p><p dir="RTL">قد يقلل ناتاليزوماب من عدد الصفائح الدموية المسؤولة عن التخثر في الدم. مما قد يؤدي إلى حالة تسمى نقص الصفيحات (إنخفاض في عدد صفيحات الدم) (انظر القسم 4) والذي يؤثر على تخثر الدم بحيث لا يتخثر دمك بسرعة كافية لوقف النزيف. هذا يمكن أن يؤدي إلى كدمات بالإضافة إلى مشاكل أخرى أكثر خطورة مثل النزيف المفرط. يجب أن تتحدث مع طبيبك على الفور إذا كان لديك كدمات غير مبررة ، بقع حمراء أو أرجوانية على الجلد (تسمى بثور) ، جروح الجلد التي لا تتوقف عن النزيف أو تترسب ، نزيف مطول من اللثة أو الأنف ، دم في البول أو البراز ، أو نزف في بياض عينيك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا تعطِ هذا الدواء للأطفال أو المراهقين دون سن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>وتيسابري</strong></p><p dir="RTL">أبلغ طبيبك إذا كنت تتناول أو تناولتَ مؤخرًا أو من الممكن أن تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا<strong> </strong><strong>يجب</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>تيسابري</strong> إذا كنتَ تتناول أدوية أخرى تؤثر على <strong>جهازك المناعي</strong>، بما في ذلك بعض الأدوية الأخرى التي تعالج مرض تصلب الأنسجة المتعدد &nbsp;.MS</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;قد لا تستطيع استعمال تيسابري TYSABRI إذا كنتَ تستعمل أو <strong>سبق لك</strong> استعمال أدوية تؤثر على جهازك المناعي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;<strong>لا</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>تيسابري</strong><strong> TYSABRI </strong>إذا كنتِ حاملًا ما لم<strong> </strong>تناقشي هذا الأمر مع طبيبك. وتأكدي من إبلاغ طبيبك فورًا إذا كنت<strong> </strong>حاملًا أو تعتقدين أنك حاملٌ أو إذا كنت تخططين بأن تصبحي حاملًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;<strong>&nbsp;يجب</strong><strong> </strong><strong>ألا</strong><strong> </strong><strong>تقومي</strong><strong> </strong><strong>بالرضاعة الطبيعية</strong><strong> </strong><strong>أثناء</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>تيسابري</strong><strong>.</strong><strong>TYSABRI </strong><strong>&nbsp;</strong>سيساعدك طبيبك على تحديد ما إذا كان يجب عليكِ التوقف عن الرضاعة الطبيعية، أو التوقف عن استعمال الدواء<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو كنت تقومين بالرضاعة الطبيعية أو تعتقدين أنك حاملٌ أو إذا كنت تخططين بأن تصبحي حاملًا استشيري طبيبك قبل استعمال هذا الدواء. سيراعي طبيبك تلك المخاطر التي يتعرض لها الطفل والفائدة التي تعود على الأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة</strong><strong> </strong><strong>السيارات</strong><strong> </strong><strong>واستعمال</strong><strong> </strong><strong>الماكينات</strong></p><p dir="RTL">تُعتبر الدوخة من الأعراض الجانبية الشائعة للغاية. فإذا كنت تعاني من هذا العرض، فلا يجب أن تقود السيارة أو تستخدم الماكينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>تيسابري</strong><strong>TYSABRI </strong><strong>&nbsp;على</strong><strong> </strong><strong>الصوديوم</strong><strong> </strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ملليمول (أو 23 مللغرام) من الصوديوم لكل جرعة حجمها 300 مللغرام. لذا يُعتبر في الأساس &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاؤك حقن تيسابري TYSABRI عن طريق طبيب متخصص في علاج مرض التصلب المتعدد. يمكن لطبيبك أن يستبدل دواء آخر لمرض التصلب المتعدد بدواء تيسابري TYSABRI في حال لم تظهر أي مشاكل غير طبيعية خلال علاجك السابق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;سوف &nbsp;يطلب طبيبك <strong>عمل فحوصات </strong>لاكتشاف وجود أجسام مضادة لفيروس JCوأي مشاكل أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;سوف يقوم طبيبك بالترتيب معك لإجراء <strong>أشعة بالرنين المغناطيسي</strong>، والتي سوف يعيد تكرارها عدة مرات أثناء علاجك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;<strong>للتبديل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>بعض</strong><strong> </strong><strong>أدوية مرض</strong><strong> </strong><strong>التصلب</strong><strong> </strong><strong>المتعدد</strong>، قد ينصح طبيبك بالانتظار لمدة معينة للتأكد من أن معظم أدويتك السابقة قد تم التخلص من آثارها في جسمك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تبلغ الجرعة الموصى بها للبالغين 300 ميللغرام ويتم إعطاؤها مرة واحدة كل 4 أسابيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تُعطى كل جرعة على شكل <strong>حقنتين</strong> تحت الجلد، في الفخذ أو المعدة أو الجزء الخلفي من أعلى الذراع . وتستغرق حتى 30 دقيقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;يرد في نهاية هذه النشرة ما يلزم من معلومات للأطباء وأخصائيي الرعاية الصحية عن كيفية إعداد وحقن هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استعمال تيسابري</strong><strong> TYSABRI </strong></p><p dir="RTL">إن تناول الجرعات المنتظمة من تيسابري TYSABRI هو أمر مهم، وخاصة أثناء الأشهر القليلة الأولى من العلاج. من الضروري الاستمرار في تناول الدواء طالما قررت أنت وطبيبك أن هذا الدواء سوف يساعدك. وذلك لأن المرضى الذين تناولوا جرعة واحدة أو جرعتين من تيسابري TYSABRI ثم توقفوا عن العلاج لفترة ثلاثة أشهر أو أكثر، كانوا أكثر عرضة لحدوث رد الفعل التحسسي من الدواء عند استئنافهم للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحقق من ردود الأفعال التحسسية </strong></p><p dir="RTL">قد واجه عدد قليل من المرضى ظهور حساسية كرد فعل لدواء تيسابريTYSABRI ، وقد يقوم طبيبك بفحص ردود الفعل</p><p dir="RTL">المؤدية للحساسية أثناء الحقن ولمدة ساعة واحدة بعد ذلك. انظر القسم 4 <em>الأعراض الجانبية المحتملة</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعتك</strong><strong> </strong><strong>من</strong><strong> </strong><strong>تيسابري</strong><strong> </strong><strong>TYSABRI</strong><strong> </strong><strong>&nbsp;&nbsp;&nbsp;</strong></p><p dir="RTL">إذا نسيت أن تتناول جرعتك المعتادة من تيسابريTYSABRI ، فعليك أن تقوم بالترتيب مع طبيبك للحصول على هذه الجرعة في أسرع وقت ممكن. ويمكنك عندئذ الاستمرار في تناول جرعتك من تيسابري TYSABRI كل 4 أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هل سيكون دواء تيسابري</strong><strong> TYSABRI </strong><strong>فعال دائمًا؟</strong></p><p dir="RTL">لدى عدد قليل من المرضى الذين يستعملون تيسابري TYSABRI قد يتسبب جهاز الدفاع الطبيعي بالجسم في إيقاف مفعول تيسابريTYSABRI &nbsp;مع مرور الوقت، حيث يقوم الجسم بتكوين أجسام مضادة للدواء تيسابريTYSABRI . وقد يقرر طبيبك عندها إذا كان تيسابري TYSABRI لا يعمل بكيفية سليمة بالنسبة لك عن طريق فحوصات الدم، وسوف يوقف استعمال تيسابري TYSABRI إذا استلزمت الضرورة ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك إذا كانت لديك أسئلة أخرى متعلّقة بدواء تيسابري .TYSABRI تناول دائمًا هذا الدواء كما هو مذكور في هذه النشرة أو كما وصفه لك طبيبك. يجب أن تراجع طبيبك إذا كنت غير متيقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عبارة&nbsp; &quot;تحت الجلد&quot; تُكتب اختصارًا باستخدام الحرفين SC على ملصق الحقنة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كسائر الأدوية قد يتسبب هذا الدواء في ظهور أعراض جانبية على الرغم من أنه ليس بالضرورة أن كل شخص تظهر لديه هذه الأعراض الجانبية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحدّث</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الممرضة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحال</strong><strong> </strong>إذا لاحظت أيٍّ مما يلي<strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>علامات وجود عدوى</strong><strong> </strong><strong>في</strong><strong> </strong><strong>المخ</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تغيّرات في الشخصية والتصرفات مثل التشوش، هذيان، فقدان الوعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تشنجات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;صداع / وجع في الرأس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;الغثيان/ القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تصلب الرقبة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;الحساسية الشديدة تجاه الضوء الساطع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;طفح جلدي )في أي مكان من الجسم)</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون هذه الأعراض ناتجة عن عدوى في المخ (التهاب المخ أو PML) أو الطبقة التي تغطي المخ (التهاب السحايا).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض عدوى خطيرة تتضمن:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;حمى لا يوجد لها تفسير</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;إسهالًا شديدًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;دوخة لفترة طويلة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;صداعًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;الكسل وفتور الهمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;ضعف النظر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;وجع أو احمرار العينين</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>رد الفعل التحسسي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;طفح جلدي مثير للحكة (الشرى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;انتفاخ الوجه أو الشفاه أو اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;ألم في الصدر أو عدم ارتیاح في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;زيادة أو انخفاض في ضغط الدم )سوف يُبلغك طبيبك أو الممرض بذلك في حالة قيامهم بمراقبة ضغط الدم لديك(</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هذه على الأرجح هي أعراض رد الفعل التحسسي أثناء الحقن أو بعد فترة وجيزة من الحقن.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علامات على</strong><strong> </strong><strong>وجود</strong><strong> </strong><strong>مشكلة</strong><strong> </strong><strong>محتملة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الكبد</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;اصفرار لون الجلد أو اصفرار المساحة البيضاء في العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;لون داكن غير عادي للبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;قصور في وظائف الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحدّث</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>الطبيبك أو الممرض</strong><strong> </strong><strong>على الفور</strong> إذا كنت تعاني من أي عرض جانبي مذكور أعلاه، أو كنت تعتقد أنك مصاب بأي عدوى<strong>. أبرز</strong><strong> </strong><strong>بطاقة</strong><strong> </strong><strong>التنبيه</strong><strong> </strong><strong>والنشرة</strong><strong> </strong><strong>الداخلية</strong> هذه إلى أي طبيب أو ممرض يشترك في علاجك وليس فقط إلى أخصائي علاج الأعصاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائع</strong><strong>ة</strong><strong> جدًّا</strong><strong> </strong>(قد تظهر لدى أكثر من 1 من كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;عدوى في المسالك البولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;احتقان الحلق وسيلان الأنف أو انسدادها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;رغبة في التقيؤ )الغثيان(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;ألم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تعب</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة </strong>(قد تظهر لدى حتى 1 من كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;الأنيميا الشديدة (نقص خلايا الدم الحمراء التي يمكن أن تجعل بشرتك شاحبة، ويمكن أن تجعلك تشعر بضيق التنفس أو تفتقر إلى الطاقة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;الحساسية ) <em>فرط</em><em> </em><em>الحساسية</em>(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;قشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;الطفح المصحوب بحكة (الشرى(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;الشعور بالغثيان (القيء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;صعوبة التنفس (ضيف النفس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;احمرار الوجه أو الجسم (احمرار)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;عدوى الهربس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;عدم الراحة حول مكان الحقن. قد تشعر بالألم أو الكدمات أو الاحمرار أو الحكة أو التورم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> </strong>(قد تظهر لدى 1 من كل &nbsp;100 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;رد فعل تحسسي شديد )فرط الحساسية(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الالتهاب المتقدم متعدد البؤرات لمادة الدماغ البيضاء (PML)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;الالتهابات بعد التوقف عن تناول الدواء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تورم الوجه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;زيادة في عدد خلايا الدم البيضاء (فرط الحمضات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; انخفاض في عدد صفيحات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; سهولة الإصابة بالكدمات (فُرْفُرِيَّة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (</strong><strong> </strong>قد تظهر لدى حتى 1 من كل 1000 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;عدوى الهربس في العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;الأنيميا الشديدة (انخفاض في خلايا الدم الحمراء التي يمكن أن تجعل بشرتك شاحبة، ويمكن أن تجعلك تشعر بضيق التنفس أو تفتقر إلى الطاقة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تورم شديد تحت الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;ارتفاع مستويات البيليروبين في الدم (<em>فرط بيليروبين الدم</em>) الذي قد يسبب أعراضًا مثل اصفرار الجلد والحمى والتعب</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير تكرارها من خلال البيانات المتوفرة)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;العدوى غير المعتادة في المخ والعينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تليّف الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحدث إلى طبيبك في أسرع وقت ممكن</strong> إذا كنت تعتقد أنك مصاب بأي عدوى. سوف تجد أيضًا هذه المعلومات في بطاقة تنبيه المريض التي أعطاها لك طبيبك.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL"><strong>إذا كنت تعاني من أي آثار جانبية فتحدّث إلى طبيبك</strong>. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً من خلال نظام الإبلاغ الوطني المدرج في القسم 6 من هذه النشرة. عن طريق الإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>الجانبية</strong><strong>:</strong></p><p dir="RTL">&nbsp;&bull; <strong>المملكة العربية السعودية</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:rect id="Rectangle_x0020_2"
 o:spid="_x0000_s1027" style='position:absolute;left:0;text-align:left;
 margin-left:182.6pt;margin-top:1.5pt;width:269pt;height:86pt;z-index:251654656;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز اتصالات الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; &nbsp;البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;&nbsp;الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp;&nbsp;&nbsp;دول مجلس التعاون الخليجي الأخرى</strong><strong>:</strong></p><p dir="RTL"><!--[if gte vml 1]><v:rect id="Rectangle_x0020_3"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:187.1pt;margin-top:6.5pt;width:269pt;height:23pt;z-index:251655680;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرجى الاتصال بالسُّلطة المختصة ذات الصلة</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستعمل هذا الدواء من بعد تاريخ انتهاء الصلاحية المبيّن على العبوة الداخلية والخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يُخزن في ثلاجة ) من 2 إلى 8 درجات مئوية)</p><p dir="RTL">لا يتم تجميده.</p><p dir="RTL">يمكن حفظ الحقن في عبواتها الأصلية لمدة تصل إلى 24 ساعة في درجة حرارة الغرفة (حتى 25 درجة مئوية). يجب عدم إعادة الحقن إلى الثلاجة.</p><p dir="RTL">تُحفظ الحقن في العبوة الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء إذا لاحظتَ تكوّن جسيمات في السائل و/أو إذا تغير لون السائل الموجود في الحقنه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما</strong><strong> </strong><strong>الذي</strong><strong> </strong><strong>يحتوي عليه</strong><strong> </strong><strong>تيسابري</strong><strong> TYSABRI </strong></p><p dir="RTL">المادة الفعالة هي ناتاليزوماب &nbsp;. NATALIZUMAB</p><p dir="RTL">يحتوي كل 1 مل في الحقنة مسبقة التعبئة على 150 مللغرام من ناتاليزومابNATALIZUMAB</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المكونات</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>هي</strong><strong>:</strong></p><p dir="RTL">فوسفات الصوديوم، أحادي القاعدة ، أحادي التميؤ</p><p dir="RTL">فوسفات الصوديوم، ثنائي القاعدة ، سباعي التميؤ</p><p dir="RTL">كلوريد الصوديوم. (انظر إلى القسم ٢&nbsp; &ldquo;يحتوي تيسابري<strong> </strong>على صوديوم&ldquo; &nbsp;)</p><p dir="RTL">بولي سوربات (E433) 80</p><p dir="RTL">ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سائل عديم اللون أو يميل إلى الأصفر قليلًا، ومن غائم إلى غائم قليلا .</p><p dir="RTL">تحتوي كل علبة كرتونية على حقنتين.</p><p dir="RTL">يتوفر تيسابري TYSABRI في عبوات تحتوي على حقنتين مسبقتي التعبئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك</strong><strong> </strong><strong>رخصة</strong><strong> </strong><strong>التسويق </strong></p><p dir="RTL">Biogen Netherlands B.V.</p><p dir="RTL">Prins Mauritslaan 13</p><p dir="RTL">1171 LP Badhoevedorp</p><p dir="RTL">هولندا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة</strong><strong> </strong><strong>المصنعة</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vetter Pharma-Fertigung GmbH &amp; Co. KG</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Schuetzenstrasse 87, 99-101</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ravensburg</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baden-Wuerttemberg 88212</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/ 2021 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Tysabri 150 mg solution for injection in pre-filled syringe

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL contains 150 mg of natalizumab.

Natalizumab is a recombinant humanised anti α4 integrin antibody produced in a murine cell line by recombinant DNA technology.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection)

Colourless to slightly yellow, slightly opalescent to opalescent solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1)</p><p>or</p><p>&middot;&nbsp;&nbsp;&nbsp; Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain Magnetic Resonance Imaging (MRI) or a significant increase in T2 lesion load as compared to a previous recent MRI.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy is to be initiated and continuously supervised by specialised physicians experienced in the diagnosis and treatment of neurological conditions, with timely access to MRI. Home treatment is not recommended. Administration is to be performed by a healthcare professional and patients must be monitored for early signs and symptoms of Progressive Multifocal Leukoencephalopathy (PML).</p><p>Patients treated with this medicinal product must be given the patient alert card and be informed about the risks of the medicinal product (see also package leaflet). After 2 years of treatment, patients should be re-informed about the risks &nbsp;especially the increased risk of PML, and should be instructed together with their caregivers on early signs and symptoms of PML.</p><p>&nbsp;</p><p>Resources for the management of hypersensitivity reactions and access to MRI should be available. There are limited data for the subcutaneous formulation in the Tysabri na&iuml;ve patient population (see section 4.4).</p><p>&nbsp;</p><p>Some patients may have been exposed to immunosuppressive medicinal products (e.g. mitoxantrone, cyclophosphamide, azathioprine). These medicinal products have the potential to cause prolonged immunosuppression, even after dosing is discontinued. Therefore the physician must confirm that such patients are not immunocompromised before starting treatment (see section 4.4).</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose for subcutaneous administration is 300&nbsp;mg every 4&nbsp;weeks. As each pre-filled syringe contains 150&nbsp;mg natalizumab two pre-filled syringes need to be administered to the patient.</p><p>&nbsp;</p><p>Continued therapy must be carefully reconsidered in patients who show no evidence of therapeutic benefit beyond 6&nbsp;months.</p><p>&nbsp;</p><p>Data on the safety and efficacy of natalizumab (intravenous infusion) at 2&nbsp;years were generated from controlled, double&ndash;blind studies. After 2 years continued therapy should be considered only following a reassessment of the potential for benefit and risk. Patients should be re-informed about<strong> </strong>the risk factors for PML, like duration of treatment, immunosuppressant use prior to receiving the medicinal product and the presence of anti-John Cunningham virus (JCV) antibodies (see section 4.4).</p><p><u>&nbsp;</u></p><p><em><u>Readministration</u></em></p><p>&nbsp;</p><p>The efficacy of re-administration has not been established (for safety, see section 4.4).</p><p><u>&nbsp;</u></p><p>Any switch in route of administration of the medicinal product should be made 4&nbsp;weeks after the previous dose.</p><p>&nbsp;</p><p><u>Special populations </u></p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>&nbsp;</p><p>This medicinal product is not recommended for use in patients aged over 65 due to a lack of data in this population.</p><p>&nbsp;</p><p><em><u>Renal and hepatic impairment</u></em></p><p><u>&nbsp;</u></p><p>Studies have not been conducted to examine the effects of renal or hepatic impairment.</p><p>&nbsp;</p><p>The mechanism for elimination and results from population pharmacokinetics suggest that dose adjustment would not be necessary in patients with renal or hepatic impairment.</p><p><em>&nbsp;</em></p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p>The safety and efficacy of this medicinal product in children and adolescents up to 18 years have not been established. Currently available data are described in sections 4.8 and 5.1.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For subcutaneous injection by a healthcare professional.</p><p>&nbsp;</p><p>Injections of two pre-filled syringes should be administered (total dose 300&nbsp;mg), one after the other without significant delay. The second injection should be administered no later than 30 minutes after the first injection.</p><p>&nbsp;</p><p>The sites for subcutaneous injection are the thigh, abdomen, or the posterior aspect of the upper arm. The injection should not be made into an area of the body where the skin is irritated, reddened, bruised, infected, or scarred in any way. When removing the syringe from the injection site, the plunger should be let go of while pulling the needle straight out. Letting go of the plunger will allow the needle guard to cover the needle. The second injection should be more than 3&nbsp;cm away from the first injection location (see instructions for administration at the end of the package leaflet).</p><p>&nbsp;</p><p>Patients are to be observed during the subcutaneous injections and for 1&nbsp;hour after for signs and symptoms of injection reactions including hypersensitivity.</p><p>For the first 6 doses, patients should be observed during the injection and for 1 hour after for signs and symptoms of injection reactions including hypersensitivity. After that, regardless of the route of administration, the 1-hour post-injection observation time may be reduced or removed according to clinical judgement if the patients have not experienced any injection reactions.</p><p>Tysabri 150&nbsp;mg solution for injection in pre-filled syringe is not intended for intravenous infusion and should be administered via subcutaneous injection only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Progressive multifocal leukoencephalopathy (PML).

Patients with increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies (see sections 4.4 and 4.8).

Combination with other DMTs.

Known active malignancies, except for patients with cutaneous basal cell carcinoma.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and batch number of the administered product should be clearly recorded.</p><p><u>&nbsp;</u></p><p><u>Progressive Multifocal Leukoencephalopathy (PML)</u></p><p>&nbsp;</p><p>Use of this medicinal product has been associated with an increased risk of PML,<strong> </strong>an opportunistic infection caused by JC virus, which may be fatal or result in severe disability. Due to this increased risk of developing PML, the benefits and risks of treatment should be individually reconsidered by the specialist physician and the patient; patients must be monitored at regular intervals throughout and should be instructed together with their caregivers on early signs and symptoms of PML. JC virus also causes JCV granule cell neuronopathy (GCN) which has been reported in patients treated with this medicinal product. Symptoms of JCV GCN are similar to symptoms of PML (i.e. cerebellar syndrome).</p><p>&nbsp;</p><p>The following risk factors are associated with an increased risk of PML.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; The presence of anti-JCV antibodies.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Treatment duration, especially beyond 2 years. After 2 years all patients should be re-informed about the risk of PML with the medicinal product.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Immunosuppressant use prior to receiving the medicinal product.</p><p>&nbsp;</p><p>Patients who are anti-JCV antibody positive are at an increased risk of developing PML compared to patients who are anti-JCV antibody negative. Patients who have all three risk factors for PML (i.e., are anti-JCV antibody positive <strong>and </strong>have received more than 2 years of therapy with this medicinal product <strong>and </strong>have received prior immunosuppressant therapy) have a significantly higher risk of PML.</p><p>&nbsp;</p><p>In anti-JCV antibody positive natalizumab treated patients who have not used prior immunosuppressants the level of anti-JCV antibody response (index) is associated with the level of risk for PML.</p><p>&nbsp;</p><p>In anti-JCV antibody positive patients, extended interval dosing of natalizumab (average dosing interval of approximately 6 weeks) is suggested to be associated with a lower PML risk compared to approved dosing. If utilising extended interval dosing, caution is required because the efficacy of extended interval dosing has not been established and the associated benefit risk balance is currently unknown (see section 5.1). The decrease in PML risk is based on data from intravenous route of administration.&nbsp; No clinical data are available on either the safety or efficacy of this extended interval dosing with subcutaneous route of administration.&nbsp; For further information, refer to the Physician Information and Management Guidelines.</p><p>&nbsp;</p><p>Patients considered at high risk treatment with this treatment should only be continued if the benefits outweigh the risks. For the estimation of PML risk in the different patient subgroups, please refer to the Physician Information and Management Guidelines.</p><p>&nbsp;</p><p><u>Anti-JCV antibody testing</u></p><p>&nbsp;</p><p>Anti-JCV antibody testing provides supportive information for risk stratification of treatment with this medicinal product. Testing for serum anti-JCV antibody prior to initiating therapy or in patients receiving the medicinal product with an unknown antibody status is recommended. Anti-JCV antibody negative patients may still be at risk of PML for reasons such as a new JCV infection, fluctuating antibody status or a false negative test result. Re-testing of anti-JCV antibody negative patients every 6 months is recommended. Retesting low index patients who have no history of prior immunosuppressant use every 6 months once they reach the 2 year treatment point is recommended.</p><p>&nbsp;</p><p>The anti-JCV antibody assay (ELISA) should not be used to diagnose PML. Use of plasmapheresis/plasma exchange (PLEX) or intravenous immunoglobulin (IVIg) can affect meaningful interpretation of serum anti-JCV antibody testing. Patients should not be tested for anti-JCV antibodies within 2 weeks of PLEX due to removal of antibodies from the serum, or within 6 months of IVIg (i.e. 6 months = 5x half-life for immunoglobulins).&nbsp;&nbsp;</p><p>&nbsp;</p><p>For further information on anti-JCV antibody testing please see Physician Information and Management Guidelines.</p><p>&nbsp;</p><p><u>MRI screening for PML</u></p><p>&nbsp;</p><p>Before initiation of treatment with this medicinal product, a recent (usually within 3 months) MRI should be available as a reference, and be repeated at least on a yearly basis. More frequent MRIs (e.g. on a 3 to 6 monthly basis) using an abbreviated protocol should be considered for patients at higher risk of PML. This includes:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Patients who have all three risk factors for PML (i.e., are<s> </s>anti-JCV antibody positive <strong>and </strong>have received more than 2 years of therapy with this medicinal product <strong>and </strong>have received prior immunosuppressant therapy),</p><p>or</p><p>&middot;&nbsp;&nbsp;&nbsp; Patients with a high anti-JCV antibody index who have received more than 2 years of therapy with this medicinal product and without prior history of immunosuppressant therapy.</p><p>&nbsp;</p><p>Current evidence suggests that the risk of PML is low at an index equal to or below 0.9 and increases substantially above 1.5 for patients who have been on treatment with this medicinal product for longer than 2 years (see the Physician Information and Management Guidelines for further information).</p><p>&nbsp;</p><p>No studies have been performed to evaluate the efficacy and safety of this medicinal product when switching patients from DMTs with an immunosuppressant effect. It is unknown if patients switching from these therapies to this treatment have an increased risk of PML, therefore these patients should be monitored more frequently (i.e. similarly to patients switching from immunosuppressants to this medicinal product).</p><p>&nbsp;</p><p>PML should be considered as a differential diagnosis in any MS patient taking natalizumab presenting with neurological symptoms and/or new brain lesions in MRI. Cases of asymptomatic PML based on MRI and positive JCV DNA in the cerebrospinal fluid have been reported.</p><p>&nbsp;</p><p>Physicians should refer to the Physician Information and Management Guidelines for further information on managing the risk of PML in natalizumab-treated patients.&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>If PML or JCV GCN is suspected, further dosing must be suspended until PML has been excluded. </strong></p><p>&nbsp;</p><p>The clinician should evaluate the patient to determine if the symptoms are indicative of neurological dysfunction and, if so, whether these symptoms are typical of MS or possibly suggestive of PML or JCV GCN. If any doubt exists, further evaluation, including MRI scan preferably with contrast (compared with pre-treatment baseline MRI), CSF testing for JC Viral DNA and repeat neurological assessments, should be considered as described in the Physician Information and Management Guidelines (see Educational guidance). Once the clinician has excluded PML and/or JCV GCN (if necessary, by repeating clinical, imaging and/or laboratory investigations if clinical suspicion remains), dosing may resume.</p><p>&nbsp;</p><p>The physician should be particularly alert to symptoms suggestive of PML or JCV GCN that the patient may not notice (e.g. cognitive, psychiatric symptoms or cerebellar syndrome). Patients should also be advised to inform their partner or caregivers about their treatment, since they may notice symptoms that the patient is not aware of.</p><p>&nbsp;</p><p>PML has been reported following discontinuation of this medicinal product in patients who did not have findings suggestive of PML at the time of discontinuation. Patients and physicians should continue to follow the same monitoring protocol and be alert for any new signs or symptoms that may be suggestive of PML for approximately 6 months following discontinuation of natalizumab.</p><p>&nbsp;</p><p>If a patient develops PML the dosing of this medicinal product must be permanently discontinued.</p><p>&nbsp;</p><p>Following reconstitution of the immune system in immunocompromised patients with PML improved outcome has been seen.</p><p>&nbsp;</p><p>Based on a retrospective analysis of natalizumab-treated patients, no difference was observed on 2‑year survival after PML diagnosis between patients who received PLEX and those who did not. For other considerations on the management of PML, see the Physician Information and Management Guidelines.</p><p>&nbsp;</p><p><u>PML and IRIS (Immune Reconstitution Inflammatory Syndrome)</u></p><p><u>&nbsp;</u></p><p>IRIS occurs in almost all PML patients treated with this medicinal product after withdrawal or removal of the medicinal product. IRIS is thought to result from the restoration of immune function in patients with PML, which can lead to serious neurological complications and may be fatal. Monitoring for development of IRIS and appropriate treatment of the associated inflammation during recovery from PML should be undertaken (see the Physician Information and Management Guidelines for further information).</p><p><u>&nbsp;</u></p><p><u>Infections including other opportunistic infections</u></p><p><u>&nbsp;</u></p><p>Other opportunistic infections have been reported with use of this medicinal product, primarily in patients with Crohn&rsquo;s disease who were immunocompromised or where significant comorbidity existed, however increased risk of other opportunistic infections with use of the medicinal product in patients without these co-morbidities cannot currently be excluded. Opportunistic infections were also detected in MS patients treated with this medicinal product as a monotherapy (see section 4.8).</p><p>&nbsp;</p><p>This treatment increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses. Serious, life-threatening, and sometimes fatal cases have been reported in the postmarketing setting in multiple sclerosis patients receiving the treatment (see section 4.8). If herpes encephalitis or meningitis occurs, the medicinal product should be discontinued, and appropriate treatment for herpes encephalitis or meningitis should be administered.</p><p>&nbsp;</p><p>Acute retinal necrosis (ARN) is a rare fulminant viral infection of the retina caused by the family of herpes viruses (e.g. varicella zoster). ARN has been observed in patients being administered this medicinal product and can be potentially blinding. Patients presenting with eye symptoms such as decreased visual acuity, redness and painful eye should be referred for retinal screening for ARN. Following clinical diagnosis of ARN, discontinuation of this medicinal product should be considered in these patients.</p><p>&nbsp;</p><p>Prescribers should be aware of the possibility that other opportunistic infections may occur during therapy and should include them in the differential diagnosis of infections that occur in Tysabri‑treated patients. If an opportunistic infection is suspected, dosing is to be suspended until such infections can be excluded through further evaluations.</p><p>&nbsp;</p><p>If a patient receiving this medicinal product develops an opportunistic infection, dosing of the medicinal product must be permanently discontinued.</p><p><u>&nbsp;</u></p><p><u>Educational guidance</u></p><p><u>&nbsp;</u></p><p>All physicians who intend to prescribe the medicinal product must ensure they are familiar with the Physician Information and Management Guidelines.</p><p>&nbsp;</p><p>Physicians must discuss the benefits and risks of natalizumab therapy with the patient and provide them with a patient alert card. Patients should be instructed that if they develop any infection then they should inform their physician that they are being treated with this medicinal product.</p><p>&nbsp;</p><p>Physicians should counsel patients on the importance of uninterrupted dosing, particularly in the early months of treatment (see hypersensitivity).</p><p><u>&nbsp;</u></p><p><u>Hypersensitivity</u></p><p>&nbsp;</p><p>Hypersensitivity reactions have been associated with this medicinal product, including, for the intravenous infusion, serious systemic reactions (see section 4.8).</p><p>&nbsp;</p><p>These reactions usually occurred within one&nbsp;hour after administration. The risk for hypersensitivity was greatest with early infusions and in patients re-exposed to treatment following an initial short exposure (one or two infusions) and extended period (three months or more) without treatment. However, the risk of hypersensitivity reactions should be considered for every administration.</p><p>&nbsp;</p><p>Patients are to be observed during the subcutaneous injections and for 1&nbsp;hour after, for signs and symptoms of injection reactions including hypersensitivity (see sections 4.2 and 4.8). Resources for the management of hypersensitivity reactions should be available.</p><p>&nbsp;</p><p>This medicinal product should be discontinued and appropriate therapy initiated at the first symptoms or signs of hypersensitivity.</p><p>&nbsp;</p><p>Patients who have experienced a hypersensitivity reaction must be permanently discontinued from treatment with natalizumab.</p><p>&nbsp;</p><p>There are limited data for the subcutaneous formulation in the Tysabri na&iuml;ve patient population (see section 5.1).</p><p>&nbsp;</p><p><u>Concurrent treatment with immunosuppressants</u></p><p><u>&nbsp;</u></p><p>The safety and efficacy of this medicinal product in combination with other immunosuppressive and antineoplastic therapies have not been fully established. Concurrent use of these agents with this medicinal product may increase the risk of infections, including opportunistic infections, and is contraindicated (see section 4.3).</p><p>&nbsp;</p><p>In phase 3 MS clinical trials with natalizumab intravenous infusion, concomitant treatment of relapses with a short course of corticosteroids was not associated with an increased rate of infection. Short courses of corticosteroids can be used in combination with &nbsp;this medicinal product.</p><p>&nbsp;</p><p><u>Prior treatment with immunosuppressive or immunomodulatory therapies </u></p><p>&nbsp;</p><p>Patients with a treatment history of immunosuppressant medications are at increased risk for PML.</p><p>No studies have been performed to evaluate the efficacy and safety of the medicinal product when switching patients from DMTs with an immunosuppressant effect. It is unknown if patients switching from these therapies to this medicinal product have an increased risk of PML, therefore these patients should be monitored more frequently (i.e. similarly to patients switching from immunosuppressants to &nbsp;this medicinal product, see MRI screening for PML).</p><p>&nbsp;</p><p>Care should be taken with patients who have previously received immunosuppressants to allow sufficient time for immune function recovery to occur. Physicians must evaluate each individual case to determine whether there is evidence of an immunocompromised state prior to commencing treatment (see section 4.3).</p><p>&nbsp;</p><p>When switching patients from another DMT to this medicinal product, the half-life and mode of action of the other therapy must be considered in order to avoid an additive immune effect whilst at the same time minimising the risk of disease reactivation. A Complete Blood Count (CBC, including lymphocytes) is recommended prior to initiating treatment to ensure that immune effects of the previous therapy (i.e. cytopenia) have resolved.</p><p>&nbsp;</p><p>Patients can switch directly from beta interferon or glatiramer acetate to natalizumabt providing there are no signs of relevant treatment-related abnormalities e.g. neutropenia and, lymphopenia.</p><p>&nbsp;</p><p>When switching from dimethyl fumarate, the washout period should be sufficient for lymphocyte count to recover before treatment is started.</p><p>&nbsp;</p><p>Following discontinuation of fingolimod, lymphocyte count progressively returns to normal range within 1 to 2 months after stopping therapy. The washout period should be sufficient for lymphocyte count to recover before treatment is started.</p><p>&nbsp;</p><p>Teriflunomide is eliminated slowly from the plasma. Without an accelerated elimination procedure, clearance of teriflunomide from plasma can take from several months up to 2 years. An accelerated elimination procedure as defined in the teriflunomide Summary of Product Characteristics is recommended or alternatively washout period should not be shorter than 3.5 months. Caution regarding potential concomitant immune effects is required when switching patients from teriflunomide to this medicinal product.</p><p>&nbsp;</p><p>Alemtuzumab has profound prolonged immunosuppressive effects. As the actual duration of these effects is unknown, initiating treatment with this medicinal product after alemtuzumab is not recommended unless the benefits clearly outweigh the risks for the individual patient.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p><u>&nbsp;</u></p><p>Disease exacerbations or injection related events may indicate the development of antibodies against natalizumab. In these cases the presence of antibodies should be evaluated and if these remain positive in a confirmatory test after at least 6&nbsp;weeks, treatment should be discontinued, as persistent antibodies are associated with a substantial decrease in efficacy of this medicinal product and an increased incidence of hypersensitivity reactions (see section 4.8).</p><p>&nbsp;</p><p>Since patients who have received an initial short exposure to this medicinal product and then had an extended period without treatment are at a higher risk of developing anti-natalizumab antibodies and/or hypersensitivity upon redosing, the presence of antibodies should be evaluated and if these remain positive in a confirmatory test after at least 6 weeks, the patient should not receive further treatment with natalizumab (see section 5.1).</p><p>&nbsp;</p><p><u>Hepatic events</u></p><p>&nbsp;</p><p>Spontaneous serious adverse reactions of liver injury have been reported during the post-marketing phase (see section 4.8). These liver injuries may occur at any time during treatment, even after the first dose. In some instances, the reaction reoccurred when treatment was reintroduced. Some patients with a past medical history of an abnormal liver test have experienced an exacerbation of abnormal liver test while on treatment. Patients should be monitored as appropriate for impaired liver function, and be instructed to contact their physician in case signs and symptoms suggestive of liver injury occur, such as jaundice and vomiting. In cases of significant liver injury this medicinal product should be discontinued.</p><p>&nbsp;</p><p><u>Thrombocytopenia</u></p><p><u>&nbsp;</u></p><p>Thrombocytopenia, including immune thrombocytopenic purpura (ITP), has been reported with the use of natalizumab. Delay in the diagnosis and treatment of thrombocytopenia may lead to serious and life-threatening sequelae. Patients should be instructed to report to their physician immediately if they experience any signs of unusual or prolonged bleeding, petechiae, or spontaneous bruising. If thrombocytopenia is identified, discontinuation of natalizumab should be considered.</p><p>&nbsp;</p><p><u>Stopping therapy</u></p><p>&nbsp;</p><p>If a decision is made to stop treatment with natalizumab, the physician needs to be aware that natalizumab remains in the blood, and has pharmacodynamic effects (e.g increased lymphocyte counts) for approximately 12&nbsp;weeks following the last dose. Starting other therapies during this interval will result in a concomitant exposure to natalizumab. For medicinal products such as interferon and glatiramer acetate, concomitant exposure of this duration was not associated with safety risks in clinical trials. No data are available in MS patients regarding concomitant exposure with immunosuppressant medication. Use of these medicinal products soon after the discontinuation of natalizumab may lead to an additive immunosuppressive effect. This should be carefully considered on a case‑by‑case basis, and a wash-out period of natalizumab might be appropriate. Short courses of steroids used to treat relapses were not associated with increased infections in clinical trials.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose (300 mg natalizumab), that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Natalizumab is contraindicated in combination with other DMTs (see section 4.3).</p><p>&nbsp;</p><p><u>Immunisations</u></p><p><u>&nbsp;</u></p><p>In a randomised, open label study of 60 patients with relapsing MS there was no significant difference in the humoral immune response to a recall antigen (tetanus toxoid) and only slightly slower and reduced humoral immune response to a neoantigen (keyhole limpet haemocyanin) was observed in patients who were treated with this medicinal product for 6 months compared to an untreated control group. Live vaccines have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p><u>&nbsp;</u></p><p>If a woman becomes pregnant while taking this medicinal product, discontinuation of treatment should be considered. A benefit-risk evaluation of the use of this medicinal product during pregnancy should take into account the patient&rsquo;s clinical condition and the possible return of disease activity after stopping the medicinal product.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>Data from clinical trials, a prospective pregnancy registry, post-marketing cases and available literature do not suggest an effect of this medicinal product exposure on pregnancy outcomes.</p><p><u>&nbsp;</u></p><p>The completed prospective Tysabri pregnancy registry contained 355 pregnancies with available outcomes. There were 316 live births, 29 of which were reported to have birth defects. Sixteen of the 29 were classified as major defects. The rate of defects corresponds to the defect rates reported in other pregnancy registries involving MS patients. There is no evidence of a specific pattern of birth defects with this medicinal product.</p><p>&nbsp;</p><p>There are no adequate and well-controlled studies of natalizumab therapy in pregnant women.</p><p>&nbsp;</p><p>Cases of thrombocytopenia in infants born to women exposed to natalizumab during pregnancy were reported in the postmarketing setting. Monitoring of platelet counts is recommended in neonates born to women exposed to natalizumab during pregnancy.</p><p>&nbsp;</p><p>This drug should be used during pregnancy only if clearly needed. If a woman becomes pregnant while taking natalizumab, discontinuation of natalizumab should be considered.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Natalizumab is excreted in human milk. The effect of natalizumab on newborn/infants is unknown. Breast-feeding should be discontinued during treatment with &nbsp;natalizumabt.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>&nbsp;</p><p>Reductions in female guinea pig fertility were observed in one study at doses in excess of the human dose; natalizumab did not affect male fertility. It is considered unlikely that natalizumab will affect fertility performance in humans following the maximum recommended dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tysabri has a minor influence on the ability to drive and use machines. Dizziness may occur following administration of natalizumab (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety profile observed for natalizumab administered subcutaneously was consistent with the known safety profile of natalizumab administered intravenously, with the exception of injection site pain. The overall frequency of injection site pain was common 4% (3/71) for subjects receiving natalizumab 300&nbsp;mg, every 4&nbsp;weeks, by subcutaneous administration. &nbsp;</p><p><u>&nbsp;</u></p><p>In placebo-controlled trials in 1,617 MS patients treated with natalizumab (intravenous infusion), for up to 2&nbsp;years (placebo: 1,135), adverse events leading to discontinuation of therapy occurred in 5.8% of patients treated with natalizumab (placebo: 4.8%). Over the 2‑year duration of the studies, 43.5% of patients treated with natalizumab reported adverse reactions (placebo: 39.6%).</p><p>&nbsp;</p><p>In clinical trials in 6786 patients treated with natalizumab (intravenous infusion and subcutaneous injection), the most frequently occurring adverse reactions were headache (32%), nasopharyngitis (27%), fatigue (23%), urinary tract infection (16%), nausea (15%), arthralgia (14%), and dizziness (11%) associated with natalizumab administration.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions arising from clinical studies, post-authorisation safety studies and spontaneous reports are presented in Table 1 below. Within the system organ classes they are listed under the following headings: Very common (&ge;1/10); Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1,000); Very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1: Adverse reactions </strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:680px"><thead><tr><td rowspan="2" style="vertical-align:top"><p>MedDRA System Organ Class</p></td><td colspan="5" style="vertical-align:top"><p>Frequency of adverse reactions</p></td></tr><tr><td style="vertical-align:top"><p><em>Very Common</em></p></td><td style="vertical-align:top"><p><em>Common</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>Rare </em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>Not known</em></p><p><em>&nbsp;</em></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><em>Infections and infestations </em></p></td><td style="vertical-align:top"><p>Nasopharyngitis</p><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>Herpes infection</p></td><td style="vertical-align:top"><p>Progressive multifocal leukoencephalopathy</p></td><td style="vertical-align:top"><p>Herpes ophthalmic</p></td><td style="vertical-align:top"><p>Meningoencephalitis herpetic</p><p>JC virus granule cell neuropathy</p><p>Necrotising herpetic retinopathy</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p><p>Immune reconstitution inflammatory syndrome</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Thrombocytopenia,</p><p>Immune thrombocytopenic purpura (ITP), Eosinophilia</p></td><td style="vertical-align:top"><p>Haemolytic anaemia</p><p>Nucleated red cells</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperbilirubinaemia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver injury</p></td></tr><tr><td style="vertical-align:top"><p><em>Investigations </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased</p><p>Drug specific antibody present</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Injury, poisoning and procedural complications </em></p></td><td style="vertical-align:top"><p>Infusion related reaction</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Pyrexia&nbsp;</p><p>Chills</p><p>Infusion site reaction</p><p>Injection site reaction</p></td><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Rash</p><p>Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders </em></p></td><td style="vertical-align:top"><p>Dizziness Headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders </em></p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em><u>Hypersensitivity reactions</u></em></p><p><em><u>&nbsp;</u></em></p><p>Hypersensitivity reactions usually occurred within one hour after completion of the subcutaneous injections. The number of patients analysed in the DELIVER and REFINE studies was low (see section 5.1).</p><p>&nbsp;</p><p>In 2-year controlled clinical trials in MS patients receiving natalizumab intravenously, hypersensitivity reactions occurred in up to 4% of patients. Anaphylactic/anaphylactoid reactions occurred in less than 1% of patients receiving this medicinal product. Hypersensitivity reactions usually occurred during the infusion or within the 1‑hour period after the completion of the infusion (see section 4.4). In post-marketing experience, there have been reports of hypersensitivity reactions which have occurred with one or more of the following associated symptoms: hypotension, hypertension, chest pain, chest discomfort, dyspnoea, angioedema, in addition to more usual symptoms such as rash and urticaria.</p><p>&nbsp;</p><p><em><u>Immunogenicity</u></em></p><p>&nbsp;</p><p>In 10% of patients antibodies against natalizumab were detected in 2-year controlled clinical trials in MS patients receiving natalizumab intravenously. Persistent anti-natalizumab antibodies (one positive test reproducible on retesting at least 6&nbsp;weeks later) developed in approximately 6% of patients. Antibodies were detected on only one occasion in an additional 4% of patients. Persistent antibodies were associated with a substantial decrease in the effectiveness of natalizumab and an increased incidence of hypersensitivity reactions. Additional infusion-related reactions associated with persistent antibodies included rigors, nausea, vomiting and flushing (see section 4.4). In the 32-week DELIVER study in MS patients with no prior exposure to natalizumab, persistent anti-natalizumab antibodies developed in 1 subject (4%) from 26 subjects who received natalizumab subcutaneously.&nbsp; Antibodies were detected on only one occasion in another 5 subjects (19%). In the 60-week REFINE study in MS patients, no subjects (136 subjects) who switched from natalizumab intravenous administration to subcutaneous administration had detectable ADA during the study (see section 5.1).&nbsp;&nbsp;</p><p>&nbsp;</p><p>If, after approximately 6&nbsp;months of therapy, persistent antibodies are suspected, either due to reduced efficacy or due to occurrence of infusion-related events, they may be detected and confirmed with a subsequent test 6&nbsp;weeks after the first positive test. Given that efficacy may be reduced or the incidence of hypersensitivity or infusion-related reactions may be increased in a patient with persistent antibodies, treatment should be discontinued in patients who develop persistent antibodies.</p><p>&nbsp;</p><p><em><u>Infections, including PML and opportunistic infections</u></em></p><p><strong>&nbsp;</strong></p><p>In 2-year controlled clinical trials in MS patients, the rate of infection was approximately 1.5 per patient‑year in both natalizumab (intravenously)- and placebo‑treated patients. The nature of the infections was generally similar in natalizumab- and placebo‑treated patients. A case of <em>cryptosporidium</em> diarrhoea was reported in MS clinical trials. In other clinical trials, cases of additional opportunistic infections have been reported, some of which were fatal. The majority of patients did not interrupt natalizumab therapy during infections and recovery occurred with appropriate treatment.</p><p>&nbsp;</p><p>In clinical trials (intravenous formulation), herpes infections (Varicella-Zoster virus, Herpes-simplex virus) occurred slightly more frequently in natalizumab-treated patients than in placebo-treated patients. In post-marketing experience, serious, life-threatening, and sometimes fatal cases of encephalitis and meningitis caused by herpes simplex or varicella zoster have been reported in multiple sclerosis patients receiving natalizumab. The duration of treatment with natalizumab prior to onset ranged from a few months to several years (see section 4.4).</p><p>&nbsp;</p><p>In postmarketing experience, rare cases of ARN have been observed in patients receiving &nbsp;this medicinal product. Some cases have occurred in patients with central nervous system (CNS) herpes infections (e.g. herpes meningitis and encephalitis). Serious cases of ARN, either affecting one or both eyes, led to blindness in some patients. The treatment reported in these cases included anti-viral therapy and in some cases, surgery (see section 4.4).</p><p>&nbsp;</p><p>Cases of PML have been reported from clinical trials, post-marketing observational studies and post-marketing passive surveillance. PML usually leads to severe disability or<em> </em>death (see section 4.4). Cases of JCV GCN have also been reported during postmarketing use of this medicinal product Symptoms of JCV GCN are similar to PML.</p><p>&nbsp;</p><p><em><u>Hepatic events</u></em></p><p>&nbsp;</p><p>Spontaneous cases of serious liver injuries, increased liver enzymes, hyperbilirubinaemia have been reported during the post-marketing phase (see section 4.4).</p><p>&nbsp;</p><p><em><u>Anaemia and haemolytic anaemia</u></em></p><p>&nbsp;</p><p>Rare, serious cases of anaemia and haemolytic anaemia have been reported in patients treated with natalizumab in post-marketing observational studies.</p><p>&nbsp;</p><p><em><u>Malignancies</u></em></p><p>&nbsp;</p><p>No differences in incidence rates or the nature of malignancies between natalizumab- and placebo‑treated patients were observed over 2&nbsp;years of treatment. However, observation over longer treatment periods is required before any effect of natalizumab on malignancies can be excluded (see section 4.3).</p><p><em>&nbsp;</em></p><p><em><u>Effects on laboratory tests</u></em></p><p><strong>&nbsp;</strong></p><p>In 2-year controlled clinical trials in MS patients treatment with natalizumab was associated with increases in circulating lymphocytes, monocytes, eosinophils, basophils and nucleated red blood cells. Elevations in neutrophils were not seen. Increases from baseline for lymphocytes, monocytes, eosinophils and basophils ranged from 35% to 140% for individual cell types but mean cell counts remained within normal ranges with intravenous infusion administration. During treatment with this medicinal product, small reductions in haemoglobin (mean decrease 0.6&nbsp;g/dL), haematocrit (mean decrease 2%) and red blood cell counts (mean decrease 0.1&nbsp;x&nbsp;10<sup>6</sup>/L) were seen. All changes in haematological variables returned to pre‑treatment values, usually within 16&nbsp;weeks of last dose of the medicinal product and the changes were not associated with clinical symptoms. In post-marketing experience, there have also been reports of eosinophilia (eosinophil count &gt;1,500/mm<sup>3</sup>) without clinical symptoms. In such cases where therapy was discontinued the elevated eosinophil levels resolved.</p><p><u>&nbsp;</u></p><p><em><u>Thrombocytopenia </u></em></p><p>In post-marketing experience, thrombocytopenia and immune thrombocytopenic purpura (ITP) have been reported with uncommon frequency.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p><strong>&nbsp;</strong></p><p>Serious adverse events were evaluated in 621 MS paediatric patients included in a meta-analysis (see also section 5.1). Within the limitations of these data, there were no new safety signals identified in this patient population. 1 case of&nbsp;herpes meningitis was reported in the meta-analysis. No cases of PML were identified in the meta-analysis, however, PML has been reported in natalizumab-treated paediatric patients in the post-marketing setting.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p><strong>To report any side effect (s):</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&nbsp;</p><ul><li><strong>Other GCC States:</strong></li></ul><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Safety of doses higher than 300 mg has not been adequately evaluated. The maximum amount of natalizumab that can be safely administered has not been determined.</p><p>&nbsp;</p><p>There is no known antidote for natalizumab overdose. Treatment consists of discontinuation of the medicinal product and supportive therapy as needed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants, ATC code: L04AA23</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>Natalizumab is a selective adhesion-molecule inhibitor and binds to the &alpha;4‑subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils. Specifically, natalizumab binds to the &alpha;4&beta;1 integrin, blocking the interaction with its cognate receptor, vascular cell adhesion molecule‑1 (VCAM‑1), and ligands osteopontin, and an alternatively spliced domain of fibronectin, connecting segment‑1 (CS‑1). Natalizumab blocks the interaction of &alpha;4&beta;7 integrin with the mucosal addressin cell adhesion molecule‑1 (MadCAM‑1). Disruption of these molecular interactions prevents transmigration of mononuclear leukocytes across the endothelium into inflamed parenchymal tissue. A further mechanism of action of natalizumab may be to suppress ongoing inflammatory reactions in diseased tissues by inhibiting the interaction of &alpha;4‑expressing leukocytes with their ligands in the extracellular matrix and on parenchymal cells. As such, natalizumab may act to suppress inflammatory activity present at the disease site, and inhibit further recruitment of immune cells into inflamed tissues.</p><p>&nbsp;</p><p>In MS, lesions are believed to occur when activated T‑lymphocytes cross the blood‑brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells and endothelial cells of the vessel wall. The interaction between &alpha;4&beta;1 and its targets is an important component of pathological inflammation in the brain and disruption of these interactions leads to reduced inflammation. Under normal conditions, VCAM‑1 is not expressed in the brain parenchyma. However, in the presence of pro‑inflammatory cytokines, VCAM‑1 is upregulated on endothelial cells and possibly on glial cells near the sites of inflammation. In the setting of central nervous system (CNS) inflammation in MS, it is the interaction of &alpha;4&beta;1 with VCAM‑1, CS‑1 and osteopontin that mediates the firm adhesion and transmigration of leukocytes into the brain parenchyma and may perpetuate the inflammatory cascade in CNS tissue. Blockade of the molecular interactions of &alpha;4&beta;1 with its targets reduces inflammatory activity present in the brain in MS and inhibits further recruitment of immune cells into inflamed tissue, thus reducing the formation or enlargement of MS lesions.</p><p>&nbsp;</p><p>Based on PK/&alpha;4&beta;1 integrin binding relationships established in the updated population pharmacokinetic/pharmacodymanic model, the EC50 of natalizumab binding to &alpha;4&beta;1 integrin is estimated to be 2.5&nbsp;mg/L. There was no difference in &alpha;4&beta;1integrin binding after natalizumab 300&nbsp;mg every 4&nbsp;weeks was administered subcutaneously or intravenously.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p>&nbsp;</p><p>Based on similarities in pharmacokinetics and pharmacodynamics between intravenous and subcutaneous administration, the efficacy data from intravenous infusion is provided as well as those from patients receiving the subcutaneous injection.</p><p>&nbsp;</p><p><em><u>AFFIRM clinical study </u></em></p><p><u>&nbsp;</u></p><p>Efficacy as monotherapy for intravenous infusion has been evaluated in one randomised, double‑blind, placebo‑controlled study lasting 2&nbsp;years (AFFIRM study)<strong> </strong>in RRMS patients who had experienced at least 1&nbsp;clinical relapse during the year prior to entry and had a Kurtzke Expanded Disability Status Scale (EDSS) score between 0 and 5. Median age was 37&nbsp;years, with a median disease duration of 5&nbsp;years. The patients were randomised with a 2:1 ratio to receive natalizumab 300&nbsp;mg (n&nbsp;=&nbsp;627) or placebo (n&nbsp;=&nbsp;315) every 4&nbsp;weeks for up to 30&nbsp;infusions. Neurological evaluations were performed every 12&nbsp;weeks and at times of suspected relapse. MRI evaluations for T1‑weighted gadolinium (Gd)‑enhancing lesions and T2‑hyperintense lesions were performed annually.</p><p>&nbsp;</p><p>Study features and results are presented in the Table 2.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3"><p><strong>Table 2. &nbsp;AFFIRM study: Main features and results</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Design</p></td><td colspan="3"><p>Monotherapy; randomised double-blind placebo-controlled parallel-group trial for 120 weeks</p></td></tr></thead><tbody><tr><td><p>Subjects</p></td><td colspan="3"><p>RRMS (McDonald criteria)</p></td></tr><tr><td><p>Treatment</p></td><td colspan="3"><p>Placebo / Natalizumab 300&nbsp;mg i.v. every 4 weeks</p></td></tr><tr><td><p>One year endpoint</p></td><td colspan="3"><p>Relapse rate</p></td></tr><tr><td><p>Two year endpoint</p></td><td colspan="3"><p>Progression on EDSS</p></td></tr><tr><td><p>Secondary endpoints</p></td><td colspan="3"><p>Relapse rate derived variables / MRI-derived variables</p></td></tr><tr><td><p>Subjects</p></td><td><p>Placebo</p></td><td colspan="2"><p>Natalizumab</p></td></tr><tr><td><p>Randomised</p></td><td><p>315</p></td><td colspan="2"><p>627</p></td></tr><tr><td><p>Completing 1 years&nbsp;</p></td><td><p>296</p></td><td colspan="2"><p>609</p></td></tr><tr><td><p>Completing 2 years&nbsp;</p></td><td><p>285</p></td><td colspan="2"><p>589</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Age yrs, median (range)</p></td><td><p>37 (19-50)</p></td><td colspan="2"><p>36 (18-50)</p></td></tr><tr><td><p>MS-history yrs, median (range)</p></td><td><p>6.0 (0-33)</p></td><td colspan="2"><p>5.0 (0-34)</p></td></tr><tr><td><p>Time since diagnosis, yrs median (range)</p></td><td><p>2.0 (0-23)</p></td><td colspan="2"><p>2.0 (0-24)</p></td></tr><tr><td><p>Relapses in previous 12 months,</p><p>median (range)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.0 (0-5)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>1.0 (0-12)</p></td></tr><tr><td><p>EDSS-baseline, median (range)</p></td><td><p>2 (0-6.0)</p></td><td colspan="2"><p>2 (0-6.0)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>RESULTS</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Annual relapse rate</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>After one year (primary endpoint)&nbsp;</p></td><td><p>0.805</p></td><td colspan="2"><p>0.261</p></td></tr><tr><td><p>After two years</p></td><td><p>0.733</p></td><td colspan="2"><p>0.235</p></td></tr><tr><td><p>One year&nbsp;</p></td><td colspan="3"><p>Rate ratio 0.33 CI<sub>95%</sub> 0.26 ; 0.41</p></td></tr><tr><td><p>Two years</p></td><td colspan="3"><p>Rate ratio 0.32 CI<sub>95%</sub> 0.26 ; 0.40</p></td></tr><tr><td><p>Relapse free</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>After one year&nbsp;</p></td><td><p>53%</p></td><td colspan="2"><p>76%</p></td></tr><tr><td><p>After two years</p></td><td><p>41%</p></td><td colspan="2"><p>67%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Disability</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Proportion progressed<sup>1</sup>(12-week confirmation; primary outcome)</p></td><td><p>29%</p></td><td colspan="2"><p>17%</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3"><p>Hazard ratio 0.58, CI<sub>95%</sub> 0.43; 0.73, p&lt;0.001</p></td></tr><tr><td><p>Proportion progressed<sup>1</sup>(24-week confirmation)</p></td><td><p>23%</p></td><td colspan="2"><p>11%</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3"><p>Hazard ratio 0.46, CI<sub>95% </sub>0.33; 0.64, p&lt;0.001</p></td></tr><tr><td><p>MRI (0-2 years)</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Median % change in T2-hyperintense lesion volume</p></td><td><p>+8.8%</p></td><td colspan="2"><p>-9.4%</p><p>(p&lt;0.001)</p></td></tr><tr><td><p>Mean number of new or newly-enlarging T2‑hyperintense lesions</p></td><td><p>11.0</p></td><td colspan="2"><p>1.9</p><p>(p&lt;0.001)</p></td></tr><tr><td><p>Mean number of T1-hypointense lesions</p></td><td><p>4.6</p></td><td colspan="2"><p>1.1</p><p>(p&lt;0.001)</p></td></tr><tr><td><p>Mean number of Gd-enhancing lesions</p></td><td><p>1.2</p></td><td colspan="2"><p>0.1</p><p>(p&lt;0.001)</p></td></tr><tr><td colspan="4"><p><sup>1 </sup>Progression of disability was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS &gt;=1.0 sustained for 12 or 24 weeks or at least a 1.5 point increase on the EDSS from a baseline EDSS =0 sustained for 12 or 24 weeks.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>In the sub-group of patients indicated for treatment of rapidly evolving RRMS (patients with 2 or more relapses and 1 or more Gd+ lesion), the annualised relapse rate was 0.282 in the natalizumab-treated group (n&nbsp;=&nbsp;148) and 1.455 in the placebo group (n&nbsp;=&nbsp;61) (p&nbsp;&lt; 0.001). Hazard ratio for disability progression was 0.36 (95% CI: 0.17, 0.76) p&nbsp;=&nbsp;0.008. These results were obtained from a <em>post hoc</em> analysis and should be interpreted cautiously. No information on the severity of the relapses before inclusion of patients in the study is available.</p><p>&nbsp;</p><p><em><u>Tysabri Observational Program (TOP)</u></em></p><p>&nbsp;</p><p>Interim analysis of results (as of May 2015) from the ongoing Tysabri Observational Program (TOP), a phase 4, multicentre, single-arm study (n = 5,770) demonstrated that patients switching from beta interferon (n= 3,255) or glatiramer acetate (n = 1,384) to Tysabri showed a sustained, significant decrease in annualised relapse rate (p &lt; 0.0001). Mean EDSS scores remained stable over 5 years. Consistent with efficacy results observed for patients switching from beta interferon or glatiramer acetate to Tysabri, for patients switching from fingolimod (n = 147) to this medicinal product, a significant decrease in annualised relapse rate (ARR) was observed, which remained stable over 2 years, and mean EDSS scores remained similar from baseline to Year 2. The limited sample size and shorter duration of natalizumab exposure for this subgroup of patients should be considered when interpreting these data.</p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p>A post-marketing meta-analysis was conducted using data from 621 paediatric MS patients treated with natalizumab (median age 17 years, range was 7 to 18 years, 91% aged &ge;14 years). Within this analysis, a limited subset of patients with data available prior to treatment (158 of the 621 patients) demonstrated a reduction in ARR from 1.466 (95% CI 1.337, 1.604) prior to treatment to 0.110 (95% CI 0.094, 0.128).</p><p>&nbsp;</p><p><em><u>Extended interval dosing</u></em></p><p><em><u>&nbsp;</u></em></p><p>In a pre-specified, retrospective analysis of US anti-JCV antibody positive Tysabri patients intravenously administered (TOUCH registry), the risk of PML was compared between patients treated with the approved dosing interval and patients treated with extended interval dosing as identified in the last 18 months of exposure (EID, average dosing intervals of approximately 6 weeks). The majority (85%) of patients dosed with EID had received the approved dosing for &ge;1 year prior to switching to EID. The interim analysis showed a lower risk of PML in patients treated with EID (hazard ratio = 0.06, 95% CI of hazard ratio = 0.01 to 0.22). The efficacy of this medicinal product when administered with EID has not been established, and therefore the benefit/risk balance of EID is unknown (see section 4.4).</p><p>&nbsp;</p><p>Efficacy has been modelled for patients who switch to longer dosing after &ge;1 year of approved dosing with this medicinal product under intravenous administration and who did not experience a relapse in the year prior to switching. Current pharmacokinetic/pharmacodynamic statistical modelling and simulation indicate that the risk of MS disease activity for patients switching to longer dosing intervals may be higher for patients with body weight &gt;80kg or those with dosing intervals &ge;7 weeks. No prospective clinical studies have been completed to validate these findings.</p><p>&nbsp;</p><p>No clinical data are available on either the safety or efficacy&nbsp;of this extended interval dosing with the subcutaneous route of administration.</p><p>&nbsp;</p><p><em><u>REFINE clinical study (subcutaneous formulation, population pre-treated with natalizumab [intravenous infusion] for a minimum of 12 months)</u></em></p><p><em><u>&nbsp;</u></em></p><p>Subcutaneous administration was assessed in a randomised, blinded, parallel-group, phase 2 study (REFINE) exploring the safety, tolerability, and efficacy of multiple regimens of natalizumab (300&nbsp;mg intravenous every 4&nbsp;weeks, 300&nbsp;mg subcutaneous every 4&nbsp;weeks, 300&nbsp;mg intravenous every 12&nbsp;weeks, 300&nbsp;mg subcutaneous every 12&nbsp;weeks, 150&nbsp;mg intravenous every 12&nbsp;weeks and 150&nbsp;mg subcutaneous every 12&nbsp;weeks) in adult subjects (n=290) with relapsing remitting multiple sclerosis conducted over a 60&nbsp;week period.&nbsp; Subjects had received natalizumab for at least 12 months and were free from replapse for 12 months prior to randomisation.&nbsp; The primary objective of this study was to explore the effects of multiple regimens of natalizumab on disease activity and safety in subjects with RRMS.The primary endpoint of this study was the cumulative number of combined unique active (CUA) MRI lesions (sum of new Gd+ lesions on brain MRI and new or newly enlarging T2 hyperintense lesions not associated with Gd+ on T1 weighted scans). The mean CUA for the 300 mg subcutaneous every 4&nbsp;week arm was low (0.02) and comparable to the 300&nbsp;mg intravenous every 4 weeks arm (0.23). The CUA in the every 12&nbsp;week treatment arms was significantly higher than the every 4&nbsp;week treatment arms resulting in the early discontinuation of the every 12&nbsp;week arms. Due to the exploratory nature of this study, no formal efficacy comparisons were made.</p><p>&nbsp;</p><p><em><u>DELIVER clinical study (subcutaneous formulation, natalizumab na&iuml;ve population)</u></em></p><p>&nbsp;</p><p>The efficacy and safety of natalizumab for subcutaneous administration in the natalizumab na&iuml;ve MS population was evaluated in a phase 1 randomised, open-label, dose-ranging study (DELIVER). 12 subjects with RRMS and 14 subjects with secondary progressive MS were enrolled in the subcutaneous treatment arms. The study&rsquo;s primary objective was to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of single subcutaneous or intramuscular 300-mg doses of natalizumab with intravenous infusion 300-mg doses of natalizumab in patients with multiple sclerosis (MS). Secondary objectives included investigation of the safety, tolerability, and immunogenicity of repeated subcutaneous and intramuscular natalizumab doses.<strong><em> </em></strong>An exploratory endpoint of this study included the number of new Gd+ lesions on brain MRI from baseline to Week 32. &nbsp;None of the subjects treated with natalizumab had any Gd+ lesions post-baseline, regardless of their disease stage (RRMS or secondary progressive MS), assigned route of administration, or the presence of Gd+ lesions at baseline.<strong><em> </em></strong>Across the RRMS and secondary progressive MS populations, 2 patients in the natalizumab 300 mg subcutaneous group experienced relapses compared to 3 patients in the natalizumab 300 mg intravenous infusion group. Small sample sizes and inter- and intra-patient variability prevent meaningful comparisons of efficacy data between groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of natalizumab after subcutaneous administration was evaluated in 2 studies. DELIVER was a phase 1, randomised, open-label, dose-ranging study to evaluate the pharmacokinetics of subcutaneous and intramuscular natalizumab in subjects with MS (RRMS or secondary progressive MS) (n = 76). (see section 5.1 for a description of the REFINE study).</p><p>&nbsp;</p><p>An updated population pharmacokinetic analysis was conducted consisting of 11 studies (conducted with subcutaneously and intravenously administered natalizumab) and data with serial PK sampling as measured by an industry standard assay. It included over 1,286<strong>&nbsp;</strong>subjects receiving doses ranging from 1 to 6<strong>&nbsp;</strong>mg/kg and fixed doses of 150/ 300<strong>&nbsp;</strong>mg.</p><p>&nbsp;</p><p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>The absorption from the injection site to systemic circulation following SC administration was characterised by first order absorption with a model estimated delay of 3<strong>&nbsp;</strong>hours. No covariates were identified.</p><p>&nbsp;</p><p>The bioavailability of natalizumab after subcutaneous administration was 82% as estimated using the updated population pharmacokinetic analysis. After SC administration of 300 mg natalizumab, peak values (Cmax) were reached by approximately 1 week (tmax: 5.8 days, range from 2 to 7.9 days).</p><p>&nbsp;</p><p>&nbsp;The mean Cmax for RRMS participants was 35.44 &mu;g/mL (range 22.0 to 47.8 &mu;g/mL) being 33% of the peak values achieved following IV administration.</p><p>&nbsp;</p><p>Multiple subcutaneous doses of 300<strong>&nbsp;</strong>mg administered every 4<strong>&nbsp;</strong>weeks resulted in comparable C<sub>trough </sub>to 300<strong>&nbsp;</strong>mg administered intravenously every 4<strong>&nbsp;</strong>weeks. The predicted time to steady-state was approximately 24 weeks. In both intravenous and subcutaneous administration of natalizumab (every 4<strong>&nbsp;</strong>weeks) C<sub>trough </sub>values resulted in comparable &alpha;4&beta;1 integrin binding.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>Both intravenous and subcutaneous routes of administration shared the same disposition PK parameters (CL, V<sub>ss</sub> and t<sub>&frac12;</sub>) and same sets of covariates as described in the updated population pharmacokinetic analysis.</p><p>&nbsp;</p><p>Median steady-state volume of distribution was 5.58<strong>&nbsp;</strong>L (5.27-5.92<strong>&nbsp;</strong>L, 95% confidence interval).</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>Population median estimate for linear clearance was 6.21<strong>&nbsp;</strong>mL/h (5.60-6.70<strong>&nbsp;</strong>mL/h, 95% confidence interval) and the estimated median half-life was 26.8<strong>&nbsp;</strong>days. The 95<sup>th</sup> percentile interval of the terminal half-life is from 11.6 to 46.2 days.</p><p>&nbsp;</p><p>The population analysis of 1,286<strong>&nbsp;</strong>patients explored the effects of selected covariates including body weight, age, gender, presence of anti-natalizumab antibodies and formulation on pharmacokinetics. Only body weight, the presence of anti-natalizumab antibodies and the formulation used in phase 2 studies were found to influence natalizumab disposition. Natalizumab clearance increased with body weight in a less than proportional manner, such that a +/-43% change in body weight resulted in only a -38% to 36% change in clearance. The presence of persistent anti-natalizumab antibodies increased natalizumab clearance approximately 2.54-fold, consistent with reduced serum natalizumab concentrations observed in persistently antibody-positive patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.</p><p>&nbsp;</p><p>Consistent with the pharmacological activity of natalizumab, altered trafficking of lymphocytes was seen as white blood cell increases as well as increased spleen weights in most <em>in vivo</em> studies. These changes were reversible and did not appear to have any adverse toxicological consequences.</p><p>&nbsp;</p><p>In studies conducted in mice, growth and metastasis of melanoma and lymphoblastic leukaemia tumour cells was not increased by the administration of natalizumab.</p><p>&nbsp;</p><p>No clastogenic or mutagenic effects of natalizumab were observed in the Ames or human chromosomal aberration assays. Natalizumab showed no effects on <em>in vitro</em> assays of &alpha;4‑integrin‑positive tumour line proliferation or cytotoxicity.</p><p>&nbsp;</p><p>Reductions in female guinea pig fertility were observed in one study at doses in excess of the human dose; natalizumab did not affect male fertility.</p><p>&nbsp;</p><p>The effect of natalizumab on reproduction was evaluated in 5 studies, 3 in guinea pigs and 2 in <em>cynomolgus</em> monkeys. These studies showed no evidence of teratogenic effects or effects on growth of offspring. In one study in guinea pigs, a small reduction in pup survival was noted. In a study in monkeys, the number of abortions was doubled in the natalizumab 30&nbsp;mg/kg treatment groups versus matching control groups. This was the result of a high incidence of abortions in treated groups in the first cohort that was not observed in the second cohort. No effects on abortion rates were noted in any other study. A study in pregnant <em>cynomolgus </em>monkeys demonstrated natalizumab‑related changes in the foetus that included mild anaemia, reduced platelet counts, increased spleen weights and reduced liver and thymus weights. These changes were associated with increased splenic extramedullary haematopoiesis, thymic atrophy and decreased hepatic haematopoiesis. Platelet counts were also reduced in offspring born to mothers treated with natalizumab until parturition, however there was no evidence of anaemia in these offspring. All changes were observed at doses in excess of the human dose and were reversed upon clearance of natalizumab.</p><p>&nbsp;</p><p>In <em>cynomolgus</em> monkeys treated with natalizumab until parturition, low levels of natalizumab were detected in the breast milk of some animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium phosphate, monobasic, monohydrate</p><p>Sodium phosphate, dibasic, heptahydrate</p><p>Sodium chloride</p><p>Polysorbate 80 (E 433)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2˚C&nbsp;‑&nbsp;8˚C).</p><p>Do not freeze.</p><p>Keep the syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>The pre-filled syringes (PFS) can be kept in their original packaging for up to 24<strong>&nbsp;</strong>hours at room temperature (up to 25<sup>o&nbsp;</sup>C). The PFS must not be returned to refrigeration. Do not use external heat sources such as hot water to warm the PFS.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each PFS consists of a pre-filled syringe made of glass (Type 1A) with a rubber stopper and thermoplastic rigid needle shield, containing 1 mL of solution. A 27 gauge needle is pre-affixed to the syringe. Each PFS has a needle guard system that will automatically cover the exposed needle when the plunger is fully depressed.</p><p>&nbsp;</p><p>Pack size of two PFS per carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local</p><p>requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	September 2021 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>